Page last updated: 2024-12-10

morusin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

morusin: from Morus root bark; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

morusin : An extended flavonoid that is flavone substituted by hydroxy groups at positions 5, 2' and 4', a prenyl group at position 3 and a 2,2-dimethyl pyran group across positions 7 and 8. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

FloraRankFlora DefinitionFamilyFamily Definition
MorusgenusA plant genus of the family MORACEAE that is widely planted for shade.[MeSH]MoraceaeThe mulberry plant family of the order Urticales, subclass Hamamelidae, class Magnoliopsida. They have milky latex and small, petalless male or female flowers.[MeSH]

Cross-References

ID SourceID
PubMed CID5281671
CHEMBL ID464006
CHEBI ID7005
SCHEMBL ID2562778
MeSH IDM0160757

Synonyms (45)

Synonym
LS-15105
ACON1_001205
nsc-649220
MEGXP0_001039
mulberrochromene
62596-29-6
morusin
2-(2,4-dihydroxyphenyl)-5-hydroxy-8,8-dimethyl-3-(3-methylbut-2-enyl)pyrano[2,3-h]chromen-4-one
NSC649220 ,
4h,8h-benzo(1,2-b:3,4-b')dipyran-4-one, 2-(2,4-dihydroxyphenyl)-5-hydroxy-8,8-dimethyl-3-(3-methyl-2-butenyl)-
MLS000697591
smr000470930
bdbm50242014
morusin, 3
cid_5281671
TCMDC-124149 ,
BRD-K40169295-001-01-2
CHEMBL464006 ,
chebi:7005 ,
LMPK12110912
HMS2271K05
nsc 649220
unii-t4vgd5np9b
t4vgd5np9b ,
FT-0686661
2-(2,4-dihydroxyphenyl)-5-hydroxy-8,8-dimethyl-3-(3-methylbut-2-en-1-yl)-4h,8h-benzo[1,2-b:3,4-b']dipyran-4-one
SCHEMBL2562778
AC-34737
DTXSID70211641
HY-N0622
CS-6885
2-(2,4-dihydroxyphenyl)-5-hydroxy-8,8-dimethyl-3-(3-methyl-2-butenyl)-4h,8h-benzo[1,2-b:3,4-b']dipyran-4-one
2-(2,4-dihydroxyphenyl)-5-hydroxy-8,8-dimethyl-3-(3-methyl-2-butenyl)-4h,8h-benzo[1,2-b:3,4-b']dipyran-4-one, 9ci
AKOS032962066
BCP16494
2-(2,4-dihydroxyphenyl)-5-hydroxy-8,8-dimethyl-3-(3-methylbut-2-en-1-yl)pyrano[2,3-f]chromen-4(8h)-one
mfcd09953814
Q27107393
2-(2,4-dihydroxyphenyl)-5-hydroxy-8,8-dimethyl-3-(3-methylbut-2-enyl)pyrano(2,3-h)chromen-4-one
2-(2,4-dihydroxyphenyl)-5-hydroxy-8,8-dimethyl-3-(3-methyl-2-buten-1-yl)-4h,8h-benzo(1,2-b:3,4-b')dipyran-4-one
morusin [who-dd]
4h,8h-benzo(1,2-b:3,4-b')dipyran-4-one, 2-(2,4-dihydroxyphenyl)-5-hydroxy-8,8-dimethyl-3-(3-methyl-2-buten-1-yl)-
A14647
2-(2,4-dihydroxyphenyl)-5-hydroxy-3-(3-methyl-2-butenyl)-4h-6,6-dimethylpyrano- [2,3-h]-1-benzopyran-4-one
A868428

Research Excerpts

Overview

Morusin is a prenylated flavonoid found in mulberry that shows antimicrobial activity against foodborne pathogens. It is a novel blocker of STAT3 activation and may have potential in negative regulation of growth and metastasis of pancreatic tumor cells.

ExcerptReferenceRelevance
"Morusin is a prenylated flavonoid found in mulberry that shows antimicrobial activity against foodborne pathogens. "( Destruction of the cell membrane and inhibition of cell phosphatidic acid biosynthesis in Staphylococcus aureus: an explanation for the antibacterial mechanism of morusin.
Li, E; Liao, S; Liu, F; Mu, L; Pang, D; Shen, W; Wang, W; Zou, Y, 2019
)
2.15
"Morusin is a compound isolated from Morus australis (Moraceae)."( Morusin Inhibits Human Osteosarcoma via the PI3K-AKT Signaling Pathway.
Chen, J; Han, J; Weng, Q; Zhang, Y, 2020
)
2.72
"Morusin is a prenylated flavonoid isolated from the root bark of Morus alba. "( Prenylated flavonoid morusin protects against TNBS-induced colitis in rats.
Fictum, P; Gajdziok, J; Hošek, J; Pokorná, M; Rotrekl, D; Šmejkal, K; Smékal, V; Suchý, P; Vochyánová, Z, 2017
)
2.22
"Morusin is a prenylated flavonoid that has been isolated from the root bark of the mulberry tree (Morus species, Moraceae), a Chinese traditional medicine. "( Antitumor progression potential of morusin suppressing STAT3 and NFκB in human hepatoma SK-Hep1 cells.
Chen, NF; Lai, DY; Lee, YJ; Lin, WL; Tseng, TH, 2015
)
2.14
"Morusin is a novel blocker of STAT3 activation and thus may have potential in negative regulation of growth and metastasis of pancreatic tumor cells."( Blockage of STAT3 Signaling Pathway by Morusin Induces Apoptosis and Inhibits Invasion in Human Pancreatic Tumor Cells.
Ahn, KS; Kim, C; Kim, JH; Kim, SH; Lee, J; Lee, SG; Nam, D; Oh, EY; Shim, BS, 2016
)
2.15
"Morusin is a pure compound isolated from root bark of Morusaustralis (Moraceae). "( Morusin induces apoptosis and suppresses NF-kappaB activity in human colorectal cancer HT-29 cells.
Chao, CL; Lee, JC; Lin, CN; Ling, P; Liu, HS; Su, CL; Won, SJ; Wu, FL, 2008
)
3.23

Effects

Morusin has been reported to exhibit potential cytotoxic activity in several cancer cell lines. Morusin has the potential to inhibit human breast cancer cell growth in vitro and in vivo through C/EBPβ and PPARγ mediated lipoapoptosis.

ExcerptReferenceRelevance
"Morusin has been shown to exert antitumor effects."( Morusin inhibits the growth of human colorectal cancer HCT116‑derived sphere‑forming cells via the inactivation of Akt pathway.
Li, X; Ye, M; Zhou, Y, 2021
)
2.79
"Morusin has been reported to exhibit potential cytotoxic activity in several cancer cell lines."( Morusin shows potent antitumor activity for human hepatocellular carcinoma in vitro and in vivo through apoptosis induction and angiogenesis inhibition.
Gao, L; Li, H; Sun, Z; Wang, L; Wang, Q; Wang, X; Yi, C, 2017
)
2.62
"Morusin has the potential to target and kill CSCs, and can inhibit human cervical growth and migration through NF-κB attenuation mediated apoptosis induction."( Morusin inhibits human cervical cancer stem cell growth and migration through attenuation of NF-κB activity and apoptosis induction.
Dong, L; Guo, H; Lin, C; Lin, P; Wang, L; Wang, X; Yang, L; Zhang, J, 2013
)
2.55
"Morusin has the potential to inhibit human GSCs growth in vitro and in vivo through stemness attenuation, adipocyte transdifferentiation, and apoptosis induction."( Morusin inhibits glioblastoma stem cell growth in vitro and in vivo through stemness attenuation, adipocyte transdifferentiation, and apoptosis induction.
Dong, L; Guo, H; Li, H; Lin, P; Liu, C; Wang, L; Wang, Q; Wang, X; Yang, L; Zhang, J, 2016
)
2.6
"Morusin has the potential to inhibit human breast cancer cell growth in vitro and in vivo through C/EBPβ and PPARγ mediated lipoapoptosis."( Morusin suppresses breast cancer cell growth in vitro and in vivo through C/EBPβ and PPARγ mediated lipoapoptosis.
Dong, L; Gao, L; Li, H; Liu, C; Sun, Z; Wang, Q; Wang, X, 2015
)
3.3

Actions

Morusin is able to inhibit the tumor growth of transplanted H22 hepatocarcinoma in mice. Morusin has no side effects.

ExcerptReferenceRelevance
"Morusin plays a key role in the treatment of breast cancer."( Mechanism of morusin on breast cancer via network pharmacology and in vitro experiments.
Huang, Q; Li, H; Li, X; Liu, Q; Xiao, J; Zhang, Q, 2023
)
2
"Morusin is able to inhibit the tumor growth of transplanted H22 hepatocarcinoma in mice and has no side effects."( Preparation of morusin from Ramulus mori and its effects on mice with transplanted H22 hepatocarcinoma.
Ma, B; Wan, LZ; Zhang, YQ,
)
1.21

Treatment

ExcerptReferenceRelevance
"Treatment with morusin (5.0 and 10.0 mg/kg, dose orally) significantly overturned AlCl3- induced learning and memory shortages along with diminution of AlCl3-induced rise in brain AChE activity and brain oxidative stress levels."( Pharmacological Evaluation of the Recuperative Effect of Morusin Against Aluminium Trichloride (AlCl3)-Induced Memory Impairment in Rats.
Agarwal, M; Ashwathanarayana, M; Chellappan, DK; Dua, K; Gupta, G; Nammi, S; Pabreja, K, 2017
)
1.04

Dosage Studied

ExcerptRelevanceReference
"Findings will provide timely information on the safety, efficacy, and optimal dosing of t-PA to treat moderate/severe COVID-19-induced ARDS, which can be rapidly adapted to a phase III trial (NCT04357730; FDA IND 149634)."(
Abbasi, S; Abd El-Wahab, A; Abdallah, M; Abebe, G; Aca-Aca, G; Adama, S; Adefegha, SA; Adidigue-Ndiome, R; Adiseshaiah, P; Adrario, E; Aghajanian, C; Agnese, W; Ahmad, A; Ahmad, I; Ahmed, MFE; Akcay, OF; Akinmoladun, AC; Akutagawa, T; Alakavuklar, MA; Álava-Rabasa, S; Albaladejo-Florín, MJ; Alexandra, AJE; Alfawares, R; Alferiev, IS; Alghamdi, HS; Ali, I; Allard, B; Allen, JD; Almada, E; Alobaid, A; Alonso, GL; Alqahtani, YS; Alqarawi, W; Alsaleh, H; Alyami, BA; Amaral, BPD; Amaro, JT; Amin, SAW; Amodio, E; Amoo, ZA; Andia Biraro, I; Angiolella, L; Anheyer, D; Anlay, DZ; Annex, BH; Antonio-Aguirre, B; Apple, S; Arbuznikov, AV; Arinsoy, T; Armstrong, DK; Ash, S; Aslam, M; Asrie, F; Astur, DC; Atzrodt, J; Au, DW; Aucoin, M; Auerbach, EJ; Azarian, S; Ba, D; Bai, Z; Baisch, PRM; Balkissou, AD; Baltzopoulos, V; Banaszewski, M; Banerjee, S; Bao, Y; Baradwan, A; Barandika, JF; Barger, PM; Barion, MRL; Barrett, CD; Basudan, AM; Baur, LE; Baz-Rodríguez, SA; Beamer, P; Beaulant, A; Becker, DF; Beckers, C; Bedel, J; Bedlack, R; Bermúdez de Castro, JM; Berry, JD; Berthier, C; Bhattacharya, D; Biadgo, B; Bianco, G; Bianco, M; Bibi, S; Bigliardi, AP; Billheimer, D; Birnie, DH; Biswas, K; Blair, HC; Bognetti, P; Bolan, PJ; Bolla, JR; Bolze, A; Bonnaillie, P; Borlimi, R; Bórquez, J; Bottari, NB; Boulleys-Nana, JR; Brighetti, G; Brodeur, GM; Budnyak, T; Budnyk, S; Bukirwa, VD; Bulman, DM; Burm, R; Busman-Sahay, K; Butcher, TW; Cai, C; Cai, H; Cai, L; Cairati, M; Calvano, CD; Camacho-Ordóñez, A; Camela, E; Cameron, T; Campbell, BS; Cansian, RL; Cao, Y; Caporale, AS; Carciofi, AC; Cardozo, V; Carè, J; Carlos, AF; Carozza, R; Carroll, CJW; Carsetti, A; Carubelli, V; Casarotta, E; Casas, M; Caselli, G; Castillo-Lora, J; Cataldi, TRI; Cavalcante, ELB; Cavaleiro, A; Cayci, Z; Cebrián-Tarancón, C; Cedrone, E; Cella, D; Cereda, C; Ceretti, A; Ceroni, M; Cha, YH; Chai, X; Chang, EF; Chang, TS; Chanteux, H; Chao, M; Chaplin, BP; Chaturvedi, S; Chaturvedi, V; Chaudhary, DK; Chen, A; Chen, C; Chen, HY; Chen, J; Chen, JJ; Chen, K; Chen, L; Chen, Q; Chen, R; Chen, SY; Chen, TY; Chen, WM; Chen, X; Chen, Y; Cheng, G; Cheng, GJ; Cheng, J; Cheng, YH; Cheon, HG; Chew, KW; Chhoker, S; Chiu, WN; Choi, ES; Choi, MJ; Choi, SD; Chokshi, S; Chorny, M; Chu, KI; Chu, WJ; Church, AL; Cirrincione, A; Clamp, AR; Cleff, MB; Cohen, M; Coleman, RL; Collins, SL; Colombo, N; Conduit, N; Cong, WL; Connelly, MA; Connor, J; Cooley, K; Correa Ramos Leal, I; Cose, S; Costantino, C; Cottrell, M; Cui, L; Cundall, J; Cutaia, C; Cutler, CW; Cuypers, ML; da Silva Júnior, FMR; Dahal, RH; Damiani, E; Damtie, D; Dan-Li, W; Dang, Z; Dasa, SSK; Davin, A; Davis, DR; de Andrade, CM; de Jong, PL; de Oliveira, D; de Paula Dorigam, JC; Dean, A; Deepa, M; Delatour, C; Dell'Aiera, S; Delley, MF; den Boer, RB; Deng, L; Deng, Q; Depner, RM; Derdau, V; Derici, U; DeSantis, AJ; Desmarini, D; Diffo-Sonkoue, L; Divizia, M; Djenabou, A; Djordjevic, JT; Dobrovolskaia, MA; Domizi, R; Donati, A; Dong, Y; Dos Santos, M; Dos Santos, MP; Douglas, RG; Duarte, PF; Dullaart, RPF; Duscha, BD; Edwards, LA; Edwards, TE; Eichenwald, EC; El-Baba, TJ; Elashiry, M; Elashiry, MM; Elashry, SH; Elliott, A; Elsayed, R; Emerson, MS; Emmanuel, YO; Emory, TH; Endale-Mangamba, LM; Enten, GA; Estefanía-Fernández, K; Estes, JD; Estrada-Mena, FJ; Evans, S; Ezra, L; Faria de, RO; Farraj, AK; Favre, C; Feng, B; Feng, J; Feng, L; Feng, W; Feng, X; Feng, Z; Fernandes, CLF; Fernández-Cuadros, ME; Fernie, AR; Ferrari, D; Florindo, PR; Fong, PC; Fontes, EPB; Fontinha, D; Fornari, VJ; Fox, NP; Fu, Q; Fujitaka, Y; Fukuhara, K; Fumeaux, T; Fuqua, C; Fustinoni, S; Gabbanelli, V; Gaikwad, S; Gall, ET; Galli, A; Gancedo, MA; Gandhi, MM; Gao, D; Gao, K; Gao, M; Gao, Q; Gao, X; Gao, Y; Gaponenko, V; Garber, A; Garcia, EM; García-Campos, C; García-Donas, J; García-Pérez, AL; Gasparri, F; Ge, C; Ge, D; Ge, JB; Ge, X; George, I; George, LA; Germani, G; Ghassemi Tabrizi, S; Gibon, Y; Gillent, E; Gillies, RS; Gilmour, MI; Goble, S; Goh, JC; Goiri, F; Goldfinger, LE; Golian, M; Gómez, MA; Gonçalves, J; Góngora-García, OR; Gonul, I; González, MA; Govers, TM; Grant, PC; Gray, EH; Gray, JE; Green, MS; Greenwald, I; Gregory, MJ; Gretzke, D; Griffin-Nolan, RJ; Griffith, DC; Gruppen, EG; Guaita, A; Guan, P; Guan, X; Guerci, P; Guerrero, DT; Guo, M; Guo, P; Guo, R; Guo, X; Gupta, J; Guz, G; Hajizadeh, N; Hamada, H; Haman-Wabi, AB; Han, TT; Hannan, N; Hao, S; Harjola, VP; Harmon, M; Hartmann, MSM; Hartwig, JF; Hasani, M; Hawthorne, WJ; Haykal-Coates, N; Hazari, MS; He, DL; He, P; He, SG; Héau, C; Hebbar Kannur, K; Helvaci, O; Heuberger, DM; Hidalgo, F; Hilty, MP; Hirata, K; Hirsch, A; Hoffman, AM; Hoffmann, JF; Holloway, RW; Holmes, RK; Hong, S; Hongisto, M; Hopf, NB; Hörlein, R; Hoshino, N; Hou, Y; Hoven, NF; Hsieh, YY; Hsu, CT; Hu, CW; Hu, JH; Hu, MY; Hu, Y; Hu, Z; Huang, C; Huang, D; Huang, DQ; Huang, L; Huang, Q; Huang, R; Huang, S; Huang, SC; Huang, W; Huang, Y; Huffman, KM; Hung, CH; Hung, CT; Huurman, R; Hwang, SM; Hyun, S; Ibrahim, AM; Iddi-Faical, A; Immordino, P; Isla, MI; Jacquemond, V; Jacques, T; Jankowska, E; Jansen, JA; Jäntti, T; Jaque-Fernandez, F; Jarvis, GA; Jatt, LP; Jeon, JW; Jeong, SH; Jhunjhunwala, R; Ji, F; Jia, X; Jia, Y; Jian-Bo, Z; Jiang, GD; Jiang, L; Jiang, W; Jiang, WD; Jiang, Z; Jiménez-Hoyos, CA; Jin, S; Jobling, MG; John, CM; John, T; Johnson, CB; Jones, KI; Jones, WS; Joseph, OO; Ju, C; Judeinstein, P; Junges, A; Junnarkar, M; Jurkko, R; Kaleka, CC; Kamath, AV; Kang, X; Kantsadi, AL; Kapoor, M; Karim, Z; Kashuba, ADM; Kassa, E; Kasztura, M; Kataja, A; Katoh, T; Kaufman, JS; Kaupp, M; Kehinde, O; Kehrenberg, C; Kemper, N; Kerr, CW; Khan, AU; Khan, MF; Khan, ZUH; Khojasteh, SC; Kilburn, S; Kim, CG; Kim, DU; Kim, DY; Kim, HJ; Kim, J; Kim, OH; Kim, YH; King, C; Klein, A; Klingler, L; Knapp, AK; Ko, TK; Kodavanti, UP; Kolla, V; Kong, L; Kong, RY; Kong, X; Kore, S; Kortz, U; Korucu, B; Kovacs, A; Krahnert, I; Kraus, WE; Kuang, SY; Kuehn-Hajder, JE; Kurz, M; Kuśtrowski, P; Kwak, YD; Kyttaris, VC; Laga, SM; Laguerre, A; Laloo, A; Langaro, MC; Langham, MC; Lao, X; Larocca, MC; Lassus, J; Lattimer, TA; Lazar, S; Le, MH; Leal, DB; Leal, M; Leary, A; Ledermann, JA; Lee, JF; Lee, MV; Lee, NH; Leeds, CM; Leeds, JS; Lefrandt, JD; Leicht, AS; Leonard, M; Lev, S; Levy, K; Li, B; Li, C; Li, CM; Li, DH; Li, H; Li, J; Li, L; Li, LJ; Li, N; Li, P; Li, T; Li, X; Li, XH; Li, XQ; Li, XX; Li, Y; Li, Z; Li, ZY; Liao, YF; Lin, CC; Lin, MH; Lin, Y; Ling, Y; Links, TP; Lira-Romero, E; Liu, C; Liu, D; Liu, H; Liu, J; Liu, L; Liu, LP; Liu, M; Liu, T; Liu, W; Liu, X; Liu, XH; Liu, Y; Liuwantara, D; Ljumanovic, N; Lobo, L; Lokhande, K; Lopes, A; Lopes, RMRM; López-Gutiérrez, JC; López-Muñoz, MJ; López-Santamaría, M; Lorenzo, C; Lorusso, D; Losito, I; Lu, C; Lu, H; Lu, HZ; Lu, SH; Lu, SN; Lu, Y; Lu, ZY; Luboga, F; Luo, JJ; Luo, KL; Luo, Y; Lutomski, CA; Lv, W; M Piedade, MF; Ma, J; Ma, JQ; Ma, JX; Ma, N; Ma, P; Ma, S; Maciel, M; Madureira, M; Maganaris, C; Maginn, EJ; Mahnashi, MH; Maierhofer, M; Majetschak, M; Malla, TR; Maloney, L; Mann, DL; Mansuri, A; Marelli, E; Margulis, CJ; Marrella, A; Martin, BL; Martín-Francés, L; Martínez de Pinillos, M; Martínez-Navarro, EM; Martinez-Quintanilla Jimenez, D; Martínez-Velasco, A; Martínez-Villaseñor, L; Martinón-Torres, M; Martins, BA; Massongo, M; Mathew, AP; Mathews, D; Matsui, J; Matsumoto, KI; Mau, T; Maves, RC; Mayclin, SJ; Mayer, JM; Maynard, ND; Mayr, T; Mboowa, MG; McEvoy, MP; McIntyre, RC; McKay, JA; McPhail, MJW; McVeigh, AL; Mebazaa, A; Medici, V; Medina, DN; Mehmood, T; Mei-Li, C; Melku, M; Meloncelli, S; Mendes, GC; Mendoza-Velásquez, C; Mercadante, R; Mercado, MI; Merenda, MEZ; Meunier, J; Mi, SL; Michels, M; Mijatovic, V; Mikhailov, V; Milheiro, SA; Miller, DC; Ming, F; Mitsuishi, M; Miyashita, T; Mo, J; Mo, S; Modesto-Mata, M; Moeller, S; Monte, A; Monteiro, L; Montomoli, J; Moore, EE; Moore, HB; Moore, PK; Mor, MK; Moratalla-López, N; Moratilla Lapeña, L; Moreira, R; Moreno, MA; Mörk, AC; Morton, M; Mosier, JM; Mou, LH; Mougharbel, AS; Muccillo-Baisch, AL; Muñoz-Serrano, AJ; Mustafa, B; Nair, GM; Nakanishi, I; Nakanjako, D; Naraparaju, K; Nawani, N; Neffati, R; Neil, EC; Neilipovitz, D; Neira-Borrajo, I; Nelson, MT; Nery, PB; Nese, M; Nguyen, F; Nguyen, MH; Niazy, AA; Nicolaï, J; Nogueira, F; Norbäck, D; Novaretti, JV; O'Donnell, T; O'Dowd, A; O'Malley, DM; Oaknin, A; Ogata, K; Ohkubo, K; Ojha, M; Olaleye, MT; Olawande, B; Olomo, EJ; Ong, EWY; Ono, A; Onwumere, J; Ortiz Bibriesca, DM; Ou, X; Oza, AM; Ozturk, K; Özütemiz, C; Palacio-Pastrana, C; Palaparthi, A; Palevsky, PM; Pan, K; Pantanetti, S; Papachristou, DJ; Pariani, A; Parikh, CR; Parissis, J; Paroul, N; Parry, S; Patel, N; Patel, SM; Patel, VC; Pawar, S; Pefura-Yone, EW; Peixoto Andrade, BCO; Pelepenko, LE; Peña-Lora, D; Peng, S; Pérez-Moro, OS; Perez-Ortiz, AC; Perry, LM; Peter, CM; Phillips, NJ; Phillips, P; Pia Tek, J; Piner, LW; Pinto, EA; Pinto, SN; Piyachaturawat, P; Poka-Mayap, V; Polledri, E; Poloni, TE; Ponessa, G; Poole, ST; Post, AK; Potter, TM; Pressly, BB; Prouty, MG; Prudêncio, M; Pulkki, K; Pupier, C; Qian, H; Qian, ZP; Qiu, Y; Qu, G; Rahimi, S; Rahman, AU; Ramadan, H; Ramanna, S; Ramirez, I; Randolph, GJ; Rasheed, A; Rault, J; Raviprakash, V; Reale, E; Redpath, C; Rema, V; Remucal, CK; Remy, D; Ren, T; Ribeiro, LB; Riboli, G; Richards, J; Rieger, V; Rieusset, J; Riva, A; Rivabella Maknis, T; Robbins, JL; Robinson, CV; Roche-Campo, F; Rodriguez, R; Rodríguez-de-Cía, J; Rollenhagen, JE; Rosen, EP; Rub, D; Rubin, N; Rubin, NT; Ruurda, JP; Saad, O; Sabell, T; Saber, SE; Sabet, M; Sadek, MM; Saejio, A; Salinas, RM; Saliu, IO; Sande, D; Sang, D; Sangenito, LS; Santos, ALSD; Sarmiento Caldas, MC; Sassaroli, S; Sassi, V; Sato, J; Sauaia, A; Saunders, K; Saunders, PR; Savarino, SJ; Scambia, G; Scanlon, N; Schetinger, MR; Schinkel, AFL; Schladweiler, MC; Schofield, CJ; Schuepbach, RA; Schulz, J; Schwartz, N; Scorcella, C; Seeley, J; Seemann, F; Seinige, D; Sengoku, T; Seravalli, J; Sgromo, B; Shaheen, MY; Shan, L; Shanmugam, S; Shao, H; Sharma, S; Shaw, KJ; Shen, BQ; Shen, CH; Shen, P; Shen, S; Shen, Y; Shen, Z; Shi, J; Shi-Li, L; Shimoda, K; Shoji, Y; Shun, C; Silva, MA; Silva-Cardoso, J; Simas, NK; Simirgiotis, MJ; Sincock, SA; Singh, MP; Sionis, A; Siu, J; Sivieri, EM; Sjerps, MJ; Skoczen, SL; Slabon, A; Slette, IJ; Smith, MD; Smith, S; Smith, TG; Snapp, KS; Snow, SJ; Soares, MCF; Soberman, D; Solares, MD; Soliman, I; Song, J; Sorooshian, A; Sorrell, TC; Spinar, J; Staudt, A; Steinhart, C; Stern, ST; Stevens, DM; Stiers, KM; Stimming, U; Su, YG; Subbian, V; Suga, H; Sukhija-Cohen, A; Suksamrarn, A; Suksen, K; Sun, J; Sun, M; Sun, P; Sun, W; Sun, XF; Sun, Y; Sundell, J; Susan, LF; Sutjarit, N; Swamy, KV; Swisher, EM; Sykes, C; Takahashi, JA; Talmor, DS; Tan, B; Tan, ZK; Tang, L; Tang, S; Tanner, JJ; Tanwar, M; Tarazi, Z; Tarvasmäki, T; Tay, FR; Teketel, A; Temitayo, GI; Thersleff, T; Thiessen Philbrook, H; Thompson, LC; Thongon, N; Tian, B; Tian, F; Tian, Q; Timothy, AT; Tingle, MD; Titze, IR; Tolppanen, H; Tong, W; Toyoda, H; Tronconi, L; Tseng, CH; Tu, H; Tu, YJ; Tung, SY; Turpault, S; Tuynman, JB; Uemoto, AT; Ugurlu, M; Ullah, S; Underwood, RS; Ungell, AL; Usandizaga-Elio, I; Vakonakis, I; van Boxel, GI; van den Beucken, JJJP; van der Boom, T; van Slegtenhorst, MA; Vanni, JR; Vaquera, A; Vasconcellos, RS; Velayos, M; Vena, R; Ventura, G; Verso, MG; Vincent, RP; Vitale, F; Vitali, S; Vlek, SL; Vleugels, MPH; Volkmann, N; Vukelic, M; Wagner Mackenzie, B; Wairagala, P; Waller, SB; Wan, J; Wan, MT; Wan, Y; Wang, CC; Wang, H; Wang, J; Wang, JF; Wang, K; Wang, L; Wang, M; Wang, S; Wang, WM; Wang, X; Wang, Y; Wang, YD; Wang, YF; Wang, Z; Wang, ZG; Warriner, K; Weberpals, JI; Weerachayaphorn, J; Wehrli, FW; Wei, J; Wei, KL; Weinheimer, CJ; Weisbord, SD; Wen, S; Wendel Garcia, PD; Williams, JW; Williams, R; Winkler, C; Wirman, AP; Wong, S; Woods, CM; Wu, B; Wu, C; Wu, F; Wu, P; Wu, S; Wu, Y; Wu, YN; Wu, ZH; Wurtzel, JGT; Xia, L; Xia, Z; Xia, ZZ; Xiao, H; Xie, C; Xin, ZM; Xing, Y; Xing, Z; Xu, S; Xu, SB; Xu, T; Xu, X; Xu, Y; Xue, L; Xun, J; Yaffe, MB; Yalew, A; Yamamoto, S; Yan, D; Yan, H; Yan, S; Yan, X; Yang, AD; Yang, E; Yang, H; Yang, J; Yang, JL; Yang, K; Yang, M; Yang, P; Yang, Q; Yang, S; Yang, W; Yang, X; Yang, Y; Yao, JC; Yao, WL; Yao, Y; Yaqub, TB; Ye, J; Ye, W; Yen, CW; Yeter, HH; Yin, C; Yip, V; Yong-Yi, J; Yu, HJ; Yu, MF; Yu, S; Yu, W; Yu, WW; Yu, X; Yuan, P; Yuan, Q; Yue, XY; Zaia, AA; Zakhary, SY; Zalwango, F; Zamalloa, A; Zamparo, P; Zampini, IC; Zani, JL; Zeitoun, R; Zeng, N; Zenteno, JC; Zepeda-Palacio, C; Zhai, C; Zhang, B; Zhang, G; Zhang, J; Zhang, K; Zhang, Q; Zhang, R; Zhang, T; Zhang, X; Zhang, Y; Zhang, YY; Zhao, B; Zhao, D; Zhao, G; Zhao, H; Zhao, Q; Zhao, R; Zhao, S; Zhao, T; Zhao, X; Zhao, XA; Zhao, Y; Zhao, Z; Zheng, Z; Zhi-Min, G; Zhou, CL; Zhou, HD; Zhou, J; Zhou, W; Zhou, XQ; Zhou, Z; Zhu, C; Zhu, H; Zhu, L; Zhu, Y; Zitzmann, N; Zou, L; Zou, Y, 2022
)
0.72
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
trihydroxyflavoneAny hydroxyflavone carrying three hydroxy groups at unspecified positions.
extended flavonoidAny flavonoid with one or more rings fused on to the phenyl substituted benzopyran framework.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (32)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency44.66840.631035.7641100.0000AID504339
glp-1 receptor, partialHomo sapiens (human)Potency6.30960.01846.806014.1254AID624417
TDP1 proteinHomo sapiens (human)Potency20.59620.000811.382244.6684AID686978; AID686979
Smad3Homo sapiens (human)Potency22.38720.00527.809829.0929AID588855
IDH1Homo sapiens (human)Potency29.09290.005210.865235.4813AID686970
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency18.35640.00419.984825.9290AID504444
parathyroid hormone/parathyroid hormone-related peptide receptor precursorHomo sapiens (human)Potency22.38723.548119.542744.6684AID743266
flap endonuclease 1Homo sapiens (human)Potency31.62280.133725.412989.1251AID588795
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1Homo sapiens (human)Potency79.43280.425612.059128.1838AID504891
Rap guanine nucleotide exchange factor 3Homo sapiens (human)Potency56.23416.309660.2008112.2020AID720709
Alpha-synucleinHomo sapiens (human)Potency17.78280.56239.398525.1189AID652106
Guanine nucleotide-binding protein GHomo sapiens (human)Potency8.91251.995325.532750.1187AID624287
TAR DNA-binding protein 43Homo sapiens (human)Potency35.48131.778316.208135.4813AID652104
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Phosphotyrosine protein phosphatase Mycobacterium tuberculosisIC50 (µMol)5.25401.20005.04898.5114AID1402907
Polyphenol oxidase 2Agaricus bisporusIC50 (µMol)275.15000.03403.987110.0000AID1799721
Sarcoplasmic/endoplasmic reticulum calcium ATPase 1Oryctolagus cuniculus (rabbit)IC50 (µMol)43.57000.00022.81679.0000AID1652219
Prostaglandin G/H synthase 1Ovis aries (sheep)IC50 (µMol)100.00000.00032.177410.0000AID595376
Polyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)IC50 (µMol)100.00000.00011.68479.3200AID595376
Tyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)IC50 (µMol)16.21000.00053.49849.7600AID1402909; AID1773062
Polyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)IC50 (µMol)100.00000.10002.452310.0000AID595377
Prostaglandin G/H synthase 1Homo sapiens (human)IC50 (µMol)100.00000.00021.557410.0000AID403341
Prostaglandin G/H synthase 2Homo sapiens (human)IC50 (µMol)100.00000.00010.995010.0000AID403340; AID595370
Beta-secretase 1Homo sapiens (human)IC50 (µMol)59.40000.00061.619410.0000AID593981
Beta-secretase 1Homo sapiens (human)Ki64.10000.00031.35248.0000AID593982
Low molecular weight protein-tyrosine phosphatase AMycobacterium tuberculosis H37RvIC50 (µMol)4.65002.74005.39678.8000AID1402908
cAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)IC50 (µMol)0.90000.00001.146310.0000AID1351564
Tyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)IC50 (µMol)14.97001.10004.69009.5400AID1402911
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
streptokinase A precursorStreptococcus pyogenes M1 GASEC50 (µMol)1.19150.06008.9128130.5170AID1902; AID1914
Estrogen receptorRattus norvegicus (Norway rat)EC50 (µMol)1.14900.006022.3670130.5170AID1914
Estrogen receptor betaRattus norvegicus (Norway rat)EC50 (µMol)1.14900.006022.3670130.5170AID1914
ORF73Human gammaherpesvirus 8EC50 (µMol)75.00000.06008.134632.1400AID435023
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (300)

Processvia Protein(s)Taxonomy
angiogenesisRap guanine nucleotide exchange factor 3Homo sapiens (human)
adaptive immune responseRap guanine nucleotide exchange factor 3Homo sapiens (human)
signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayRap guanine nucleotide exchange factor 3Homo sapiens (human)
associative learningRap guanine nucleotide exchange factor 3Homo sapiens (human)
Rap protein signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
regulation of actin cytoskeleton organizationRap guanine nucleotide exchange factor 3Homo sapiens (human)
negative regulation of syncytium formation by plasma membrane fusionRap guanine nucleotide exchange factor 3Homo sapiens (human)
intracellular signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of GTPase activityRap guanine nucleotide exchange factor 3Homo sapiens (human)
regulation of angiogenesisRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of angiogenesisRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of protein export from nucleusRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of stress fiber assemblyRap guanine nucleotide exchange factor 3Homo sapiens (human)
regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of syncytium formation by plasma membrane fusionRap guanine nucleotide exchange factor 3Homo sapiens (human)
establishment of endothelial barrierRap guanine nucleotide exchange factor 3Homo sapiens (human)
cellular response to cAMPRap guanine nucleotide exchange factor 3Homo sapiens (human)
Ras protein signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
regulation of insulin secretionRap guanine nucleotide exchange factor 3Homo sapiens (human)
negative regulation of endothelial cell proliferationPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukocyte chemotaxis involved in inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukocyte migration involved in inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukotriene production involved in inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukotriene metabolic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
humoral immune responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of angiogenesisPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukotriene biosynthetic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
lipoxygenase pathwayPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
positive regulation of bone mineralizationPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
dendritic cell migrationPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
glucose homeostasisPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
long-chain fatty acid biosynthetic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of fat cell differentiationPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of insulin secretionPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of vascular wound healingPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of wound healingPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of inflammatory response to woundingPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of cytokine production involved in inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of cellular response to oxidative stressPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukotriene A4 biosynthetic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of reactive oxygen species biosynthetic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of response to endoplasmic reticulum stressPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of sprouting angiogenesisPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
positive regulation of leukocyte adhesion to arterial endothelial cellPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
lipoxin biosynthetic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
arachidonic acid metabolic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
lipid oxidationPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
positive regulation of JUN kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein dephosphorylationTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
insulin receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of signal transductionTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of signal transductionTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
actin cytoskeleton organizationTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of endocytosisTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of vascular endothelial growth factor receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endoplasmic reticulum unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of intracellular protein transportTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cellular response to unfolded proteinTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
peptidyl-tyrosine dephosphorylationTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
platelet-derived growth factor receptor-beta signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
IRE1-mediated unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
insulin receptor recyclingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of MAP kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of insulin receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of type I interferon-mediated signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
growth hormone receptor signaling pathway via JAK-STATTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
positive regulation of protein tyrosine kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of ERK1 and ERK2 cascadeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of hepatocyte growth factor receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
positive regulation of IRE1-mediated unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of PERK-mediated unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
peptidyl-tyrosine dephosphorylation involved in inactivation of protein kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
positive regulation of receptor catabolic processTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
linoleic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
leukotriene A4 metabolic processPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
lipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
negative regulation of muscle cell apoptotic processPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
arachidonic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
lipoxygenase pathwayPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
fatty acid oxidationPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
unsaturated fatty acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
superoxide anion generationPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
linoleic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
hepoxilin biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
establishment of skin barrierPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
negative regulation of platelet aggregationPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
leukotriene A4 metabolic processPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
lipoxin A4 biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
lipoxin B4 biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
lipid oxidationPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
prostaglandin biosynthetic processProstaglandin G/H synthase 1Homo sapiens (human)
response to oxidative stressProstaglandin G/H synthase 1Homo sapiens (human)
regulation of blood pressureProstaglandin G/H synthase 1Homo sapiens (human)
cyclooxygenase pathwayProstaglandin G/H synthase 1Homo sapiens (human)
regulation of cell population proliferationProstaglandin G/H synthase 1Homo sapiens (human)
cellular oxidant detoxificationProstaglandin G/H synthase 1Homo sapiens (human)
prostaglandin biosynthetic processProstaglandin G/H synthase 2Homo sapiens (human)
angiogenesisProstaglandin G/H synthase 2Homo sapiens (human)
response to oxidative stressProstaglandin G/H synthase 2Homo sapiens (human)
embryo implantationProstaglandin G/H synthase 2Homo sapiens (human)
learningProstaglandin G/H synthase 2Homo sapiens (human)
memoryProstaglandin G/H synthase 2Homo sapiens (human)
regulation of blood pressureProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of cell population proliferationProstaglandin G/H synthase 2Homo sapiens (human)
response to xenobiotic stimulusProstaglandin G/H synthase 2Homo sapiens (human)
response to nematodeProstaglandin G/H synthase 2Homo sapiens (human)
response to fructoseProstaglandin G/H synthase 2Homo sapiens (human)
response to manganese ionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of vascular endothelial growth factor productionProstaglandin G/H synthase 2Homo sapiens (human)
cyclooxygenase pathwayProstaglandin G/H synthase 2Homo sapiens (human)
bone mineralizationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of prostaglandin biosynthetic processProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of fever generationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of synaptic plasticityProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of synaptic transmission, dopaminergicProstaglandin G/H synthase 2Homo sapiens (human)
prostaglandin secretionProstaglandin G/H synthase 2Homo sapiens (human)
response to estradiolProstaglandin G/H synthase 2Homo sapiens (human)
response to lipopolysaccharideProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylationProstaglandin G/H synthase 2Homo sapiens (human)
response to vitamin DProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to heatProstaglandin G/H synthase 2Homo sapiens (human)
response to tumor necrosis factorProstaglandin G/H synthase 2Homo sapiens (human)
maintenance of blood-brain barrierProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of protein import into nucleusProstaglandin G/H synthase 2Homo sapiens (human)
hair cycleProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of apoptotic processProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of nitric oxide biosynthetic processProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of cell cycleProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of vasoconstrictionProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of smooth muscle contractionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of smooth muscle contractionProstaglandin G/H synthase 2Homo sapiens (human)
decidualizationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of smooth muscle cell proliferationProstaglandin G/H synthase 2Homo sapiens (human)
regulation of inflammatory responseProstaglandin G/H synthase 2Homo sapiens (human)
brown fat cell differentiationProstaglandin G/H synthase 2Homo sapiens (human)
response to glucocorticoidProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of calcium ion transportProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of synaptic transmission, glutamatergicProstaglandin G/H synthase 2Homo sapiens (human)
response to fatty acidProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to mechanical stimulusProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to lead ionProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to ATPProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to hypoxiaProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to non-ionic osmotic stressProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to fluid shear stressProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of transforming growth factor beta productionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of cell migration involved in sprouting angiogenesisProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of fibroblast growth factor productionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of brown fat cell differentiationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of platelet-derived growth factor productionProstaglandin G/H synthase 2Homo sapiens (human)
cellular oxidant detoxificationProstaglandin G/H synthase 2Homo sapiens (human)
regulation of neuroinflammatory responseProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to osmotic stressProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to homocysteineProstaglandin G/H synthase 2Homo sapiens (human)
response to angiotensinProstaglandin G/H synthase 2Homo sapiens (human)
calcium ion homeostasisAlpha-synucleinHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIAlpha-synucleinHomo sapiens (human)
microglial cell activationAlpha-synucleinHomo sapiens (human)
positive regulation of receptor recyclingAlpha-synucleinHomo sapiens (human)
positive regulation of neurotransmitter secretionAlpha-synucleinHomo sapiens (human)
negative regulation of protein kinase activityAlpha-synucleinHomo sapiens (human)
fatty acid metabolic processAlpha-synucleinHomo sapiens (human)
neutral lipid metabolic processAlpha-synucleinHomo sapiens (human)
phospholipid metabolic processAlpha-synucleinHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
mitochondrial membrane organizationAlpha-synucleinHomo sapiens (human)
adult locomotory behaviorAlpha-synucleinHomo sapiens (human)
response to xenobiotic stimulusAlpha-synucleinHomo sapiens (human)
response to iron(II) ionAlpha-synucleinHomo sapiens (human)
regulation of phospholipase activityAlpha-synucleinHomo sapiens (human)
negative regulation of platelet-derived growth factor receptor signaling pathwayAlpha-synucleinHomo sapiens (human)
regulation of glutamate secretionAlpha-synucleinHomo sapiens (human)
regulation of dopamine secretionAlpha-synucleinHomo sapiens (human)
synaptic vesicle exocytosisAlpha-synucleinHomo sapiens (human)
synaptic vesicle primingAlpha-synucleinHomo sapiens (human)
regulation of transmembrane transporter activityAlpha-synucleinHomo sapiens (human)
negative regulation of microtubule polymerizationAlpha-synucleinHomo sapiens (human)
receptor internalizationAlpha-synucleinHomo sapiens (human)
protein destabilizationAlpha-synucleinHomo sapiens (human)
response to magnesium ionAlpha-synucleinHomo sapiens (human)
negative regulation of transporter activityAlpha-synucleinHomo sapiens (human)
response to lipopolysaccharideAlpha-synucleinHomo sapiens (human)
negative regulation of monooxygenase activityAlpha-synucleinHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationAlpha-synucleinHomo sapiens (human)
response to type II interferonAlpha-synucleinHomo sapiens (human)
cellular response to oxidative stressAlpha-synucleinHomo sapiens (human)
SNARE complex assemblyAlpha-synucleinHomo sapiens (human)
positive regulation of SNARE complex assemblyAlpha-synucleinHomo sapiens (human)
regulation of locomotionAlpha-synucleinHomo sapiens (human)
dopamine biosynthetic processAlpha-synucleinHomo sapiens (human)
mitochondrial ATP synthesis coupled electron transportAlpha-synucleinHomo sapiens (human)
regulation of macrophage activationAlpha-synucleinHomo sapiens (human)
positive regulation of apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of neuron apoptotic processAlpha-synucleinHomo sapiens (human)
positive regulation of endocytosisAlpha-synucleinHomo sapiens (human)
negative regulation of exocytosisAlpha-synucleinHomo sapiens (human)
positive regulation of exocytosisAlpha-synucleinHomo sapiens (human)
regulation of long-term neuronal synaptic plasticityAlpha-synucleinHomo sapiens (human)
synaptic vesicle endocytosisAlpha-synucleinHomo sapiens (human)
synaptic vesicle transportAlpha-synucleinHomo sapiens (human)
positive regulation of inflammatory responseAlpha-synucleinHomo sapiens (human)
regulation of acyl-CoA biosynthetic processAlpha-synucleinHomo sapiens (human)
protein tetramerizationAlpha-synucleinHomo sapiens (human)
positive regulation of release of sequestered calcium ion into cytosolAlpha-synucleinHomo sapiens (human)
neuron apoptotic processAlpha-synucleinHomo sapiens (human)
dopamine uptake involved in synaptic transmissionAlpha-synucleinHomo sapiens (human)
negative regulation of dopamine uptake involved in synaptic transmissionAlpha-synucleinHomo sapiens (human)
negative regulation of serotonin uptakeAlpha-synucleinHomo sapiens (human)
regulation of norepinephrine uptakeAlpha-synucleinHomo sapiens (human)
negative regulation of norepinephrine uptakeAlpha-synucleinHomo sapiens (human)
excitatory postsynaptic potentialAlpha-synucleinHomo sapiens (human)
long-term synaptic potentiationAlpha-synucleinHomo sapiens (human)
positive regulation of inositol phosphate biosynthetic processAlpha-synucleinHomo sapiens (human)
negative regulation of thrombin-activated receptor signaling pathwayAlpha-synucleinHomo sapiens (human)
response to interleukin-1Alpha-synucleinHomo sapiens (human)
cellular response to copper ionAlpha-synucleinHomo sapiens (human)
cellular response to epinephrine stimulusAlpha-synucleinHomo sapiens (human)
positive regulation of protein serine/threonine kinase activityAlpha-synucleinHomo sapiens (human)
supramolecular fiber organizationAlpha-synucleinHomo sapiens (human)
negative regulation of mitochondrial electron transport, NADH to ubiquinoneAlpha-synucleinHomo sapiens (human)
positive regulation of glutathione peroxidase activityAlpha-synucleinHomo sapiens (human)
positive regulation of hydrogen peroxide catabolic processAlpha-synucleinHomo sapiens (human)
regulation of synaptic vesicle recyclingAlpha-synucleinHomo sapiens (human)
regulation of reactive oxygen species biosynthetic processAlpha-synucleinHomo sapiens (human)
positive regulation of protein localization to cell peripheryAlpha-synucleinHomo sapiens (human)
negative regulation of chaperone-mediated autophagyAlpha-synucleinHomo sapiens (human)
regulation of presynapse assemblyAlpha-synucleinHomo sapiens (human)
amyloid fibril formationAlpha-synucleinHomo sapiens (human)
synapse organizationAlpha-synucleinHomo sapiens (human)
chemical synaptic transmissionAlpha-synucleinHomo sapiens (human)
proteolysisBeta-secretase 1Homo sapiens (human)
membrane protein ectodomain proteolysisBeta-secretase 1Homo sapiens (human)
response to lead ionBeta-secretase 1Homo sapiens (human)
protein processingBeta-secretase 1Homo sapiens (human)
amyloid-beta formationBeta-secretase 1Homo sapiens (human)
amyloid precursor protein catabolic processBeta-secretase 1Homo sapiens (human)
positive regulation of neuron apoptotic processBeta-secretase 1Homo sapiens (human)
amyloid-beta metabolic processBeta-secretase 1Homo sapiens (human)
detection of mechanical stimulus involved in sensory perception of painBeta-secretase 1Homo sapiens (human)
prepulse inhibitionBeta-secretase 1Homo sapiens (human)
cellular response to copper ionBeta-secretase 1Homo sapiens (human)
cellular response to manganese ionBeta-secretase 1Homo sapiens (human)
presynaptic modulation of chemical synaptic transmissionBeta-secretase 1Homo sapiens (human)
signaling receptor ligand precursor processingBeta-secretase 1Homo sapiens (human)
cellular response to amyloid-betaBeta-secretase 1Homo sapiens (human)
amyloid fibril formationBeta-secretase 1Homo sapiens (human)
negative regulation of inflammatory response to antigenic stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
renal water homeostasisGuanine nucleotide-binding protein GHomo sapiens (human)
G protein-coupled receptor signaling pathwayGuanine nucleotide-binding protein GHomo sapiens (human)
regulation of insulin secretionGuanine nucleotide-binding protein GHomo sapiens (human)
cellular response to glucagon stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
symbiont-mediated suppression of host apoptosisLow molecular weight protein-tyrosine phosphatase AMycobacterium tuberculosis H37Rv
protein dephosphorylationTyrosine-protein phosphatase non-receptor type 12Homo sapiens (human)
peptidyl-tyrosine dephosphorylationTyrosine-protein phosphatase non-receptor type 12Homo sapiens (human)
regulation of epidermal growth factor receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 12Homo sapiens (human)
tissue regenerationTyrosine-protein phosphatase non-receptor type 12Homo sapiens (human)
cellular response to epidermal growth factor stimulusTyrosine-protein phosphatase non-receptor type 12Homo sapiens (human)
negative regulation of ERBB signaling pathwayTyrosine-protein phosphatase non-receptor type 12Homo sapiens (human)
negative regulation of platelet-derived growth factor receptor-beta signaling pathwayTyrosine-protein phosphatase non-receptor type 12Homo sapiens (human)
regulation of heart ratecAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
cAMP catabolic processcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
positive regulation of heart ratecAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
regulation of release of sequestered calcium ion into cytosol by sarcoplasmic reticulumcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
positive regulation of type II interferon productioncAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
positive regulation of interleukin-2 productioncAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
positive regulation of interleukin-5 productioncAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
negative regulation of peptidyl-serine phosphorylationcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
negative regulation of heart contractioncAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
T cell receptor signaling pathwaycAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
establishment of endothelial barriercAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
adrenergic receptor signaling pathwaycAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
regulation of cardiac muscle cell contractioncAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
negative regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathwaycAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
regulation of cell communication by electrical coupling involved in cardiac conductioncAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
negative regulation of relaxation of cardiac musclecAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
regulation of calcium ion transmembrane transport via high voltage-gated calcium channelcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
cAMP-mediated signalingcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
negative regulation of protein phosphorylationTAR DNA-binding protein 43Homo sapiens (human)
mRNA processingTAR DNA-binding protein 43Homo sapiens (human)
RNA splicingTAR DNA-binding protein 43Homo sapiens (human)
negative regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
regulation of protein stabilityTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of insulin secretionTAR DNA-binding protein 43Homo sapiens (human)
response to endoplasmic reticulum stressTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of protein import into nucleusTAR DNA-binding protein 43Homo sapiens (human)
regulation of circadian rhythmTAR DNA-binding protein 43Homo sapiens (human)
regulation of apoptotic processTAR DNA-binding protein 43Homo sapiens (human)
negative regulation by host of viral transcriptionTAR DNA-binding protein 43Homo sapiens (human)
rhythmic processTAR DNA-binding protein 43Homo sapiens (human)
regulation of cell cycleTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA destabilizationTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA stabilizationTAR DNA-binding protein 43Homo sapiens (human)
nuclear inner membrane organizationTAR DNA-binding protein 43Homo sapiens (human)
amyloid fibril formationTAR DNA-binding protein 43Homo sapiens (human)
regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
protein dephosphorylationTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
lipid metabolic processTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
autophagyTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
negative regulation of autophagyTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
positive regulation of gene expressionTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
negative regulation of gene expressionTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
T cell differentiationTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
lipopolysaccharide-mediated signaling pathwayTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
positive regulation of type I interferon productionTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
response to lipopolysaccharideTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
negative regulation of interleukin-6 productionTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
negative regulation of interleukin-8 productionTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
negative regulation of tumor necrosis factor productionTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
positive regulation of type II interferon productionTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
regulation of natural killer cell proliferationTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
positive regulation of toll-like receptor 3 signaling pathwayTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
positive regulation of toll-like receptor 4 signaling pathwayTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
phosphoanandamide dephosphorylationTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
negative regulation of JUN kinase activityTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
regulation of innate immune responseTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
T cell receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
regulation of B cell receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
negative regulation of T cell receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
negative regulation of T cell activationTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
negative regulation of nucleotide-binding oligomerization domain containing 2 signaling pathwayTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
cellular response to muramyl dipeptideTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
positive regulation of NLRP3 inflammasome complex assemblyTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
regulation of non-canonical NF-kappaB signal transductionTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
positive regulation of protein K63-linked ubiquitinationTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
negative regulation of p38MAPK cascadeTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (82)

Processvia Protein(s)Taxonomy
guanyl-nucleotide exchange factor activityRap guanine nucleotide exchange factor 3Homo sapiens (human)
protein bindingRap guanine nucleotide exchange factor 3Homo sapiens (human)
protein domain specific bindingRap guanine nucleotide exchange factor 3Homo sapiens (human)
cAMP bindingRap guanine nucleotide exchange factor 3Homo sapiens (human)
arachidonate 5-lipoxygenase activityPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
arachidonate 12(S)-lipoxygenase activityPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
iron ion bindingPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
protein bindingPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
hydrolase activityPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
arachidonate 8(S)-lipoxygenase activityPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
RNA bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
insulin receptor bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
zinc ion bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
enzyme bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein kinase bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
receptor tyrosine kinase bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cadherin bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
ephrin receptor bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein phosphatase 2A bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
non-membrane spanning protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
arachidonate 12(S)-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
iron ion bindingPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
protein bindingPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
linoleate 13S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
hepoxilin-epoxide hydrolase activityPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
arachidonate 15-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
peroxidase activityProstaglandin G/H synthase 1Homo sapiens (human)
prostaglandin-endoperoxide synthase activityProstaglandin G/H synthase 1Homo sapiens (human)
protein bindingProstaglandin G/H synthase 1Homo sapiens (human)
heme bindingProstaglandin G/H synthase 1Homo sapiens (human)
metal ion bindingProstaglandin G/H synthase 1Homo sapiens (human)
oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygenProstaglandin G/H synthase 1Homo sapiens (human)
peroxidase activityProstaglandin G/H synthase 2Homo sapiens (human)
prostaglandin-endoperoxide synthase activityProstaglandin G/H synthase 2Homo sapiens (human)
protein bindingProstaglandin G/H synthase 2Homo sapiens (human)
enzyme bindingProstaglandin G/H synthase 2Homo sapiens (human)
heme bindingProstaglandin G/H synthase 2Homo sapiens (human)
protein homodimerization activityProstaglandin G/H synthase 2Homo sapiens (human)
metal ion bindingProstaglandin G/H synthase 2Homo sapiens (human)
oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygenProstaglandin G/H synthase 2Homo sapiens (human)
fatty acid bindingAlpha-synucleinHomo sapiens (human)
phospholipase D inhibitor activityAlpha-synucleinHomo sapiens (human)
SNARE bindingAlpha-synucleinHomo sapiens (human)
magnesium ion bindingAlpha-synucleinHomo sapiens (human)
transcription cis-regulatory region bindingAlpha-synucleinHomo sapiens (human)
actin bindingAlpha-synucleinHomo sapiens (human)
protein kinase inhibitor activityAlpha-synucleinHomo sapiens (human)
copper ion bindingAlpha-synucleinHomo sapiens (human)
calcium ion bindingAlpha-synucleinHomo sapiens (human)
protein bindingAlpha-synucleinHomo sapiens (human)
phospholipid bindingAlpha-synucleinHomo sapiens (human)
ferrous iron bindingAlpha-synucleinHomo sapiens (human)
zinc ion bindingAlpha-synucleinHomo sapiens (human)
lipid bindingAlpha-synucleinHomo sapiens (human)
oxidoreductase activityAlpha-synucleinHomo sapiens (human)
kinesin bindingAlpha-synucleinHomo sapiens (human)
Hsp70 protein bindingAlpha-synucleinHomo sapiens (human)
histone bindingAlpha-synucleinHomo sapiens (human)
identical protein bindingAlpha-synucleinHomo sapiens (human)
alpha-tubulin bindingAlpha-synucleinHomo sapiens (human)
cysteine-type endopeptidase inhibitor activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
tau protein bindingAlpha-synucleinHomo sapiens (human)
phosphoprotein bindingAlpha-synucleinHomo sapiens (human)
molecular adaptor activityAlpha-synucleinHomo sapiens (human)
dynein complex bindingAlpha-synucleinHomo sapiens (human)
cuprous ion bindingAlpha-synucleinHomo sapiens (human)
amyloid-beta bindingBeta-secretase 1Homo sapiens (human)
endopeptidase activityBeta-secretase 1Homo sapiens (human)
aspartic-type endopeptidase activityBeta-secretase 1Homo sapiens (human)
protein bindingBeta-secretase 1Homo sapiens (human)
peptidase activityBeta-secretase 1Homo sapiens (human)
beta-aspartyl-peptidase activityBeta-secretase 1Homo sapiens (human)
enzyme bindingBeta-secretase 1Homo sapiens (human)
protein serine/threonine kinase bindingBeta-secretase 1Homo sapiens (human)
G protein activityGuanine nucleotide-binding protein GHomo sapiens (human)
adenylate cyclase activator activityGuanine nucleotide-binding protein GHomo sapiens (human)
protein tyrosine phosphatase activityLow molecular weight protein-tyrosine phosphatase AMycobacterium tuberculosis H37Rv
phosphoprotein phosphatase activityTyrosine-protein phosphatase non-receptor type 12Homo sapiens (human)
protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 12Homo sapiens (human)
non-membrane spanning protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 12Homo sapiens (human)
protein bindingTyrosine-protein phosphatase non-receptor type 12Homo sapiens (human)
SH3 domain bindingTyrosine-protein phosphatase non-receptor type 12Homo sapiens (human)
3',5'-cyclic-nucleotide phosphodiesterase activitycAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
3',5'-cyclic-AMP phosphodiesterase activitycAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
calcium channel regulator activitycAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
protein bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
enzyme bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
signaling receptor regulator activitycAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
cAMP bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
beta-2 adrenergic receptor bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
transmembrane transporter bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
metal ion bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
ATPase bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
scaffold protein bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
heterocyclic compound bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
3',5'-cyclic-GMP phosphodiesterase activitycAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
double-stranded DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
RNA bindingTAR DNA-binding protein 43Homo sapiens (human)
mRNA 3'-UTR bindingTAR DNA-binding protein 43Homo sapiens (human)
protein bindingTAR DNA-binding protein 43Homo sapiens (human)
lipid bindingTAR DNA-binding protein 43Homo sapiens (human)
identical protein bindingTAR DNA-binding protein 43Homo sapiens (human)
pre-mRNA intronic bindingTAR DNA-binding protein 43Homo sapiens (human)
molecular condensate scaffold activityTAR DNA-binding protein 43Homo sapiens (human)
protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
non-membrane spanning protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
protein bindingTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
phosphatase activityTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
SH3 domain bindingTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
kinase bindingTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
ubiquitin protein ligase bindingTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (78)

Processvia Protein(s)Taxonomy
plasma membraneRap guanine nucleotide exchange factor 3Homo sapiens (human)
cortical actin cytoskeletonRap guanine nucleotide exchange factor 3Homo sapiens (human)
plasma membraneRap guanine nucleotide exchange factor 3Homo sapiens (human)
microvillusRap guanine nucleotide exchange factor 3Homo sapiens (human)
endomembrane systemRap guanine nucleotide exchange factor 3Homo sapiens (human)
membraneRap guanine nucleotide exchange factor 3Homo sapiens (human)
lamellipodiumRap guanine nucleotide exchange factor 3Homo sapiens (human)
filopodiumRap guanine nucleotide exchange factor 3Homo sapiens (human)
extracellular exosomeRap guanine nucleotide exchange factor 3Homo sapiens (human)
extracellular regionPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
extracellular spacePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nuclear envelopePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nuclear envelope lumenPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nucleoplasmPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
cytosolPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nuclear matrixPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nuclear membranePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
secretory granule lumenPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
perinuclear region of cytoplasmPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
ficolin-1-rich granule lumenPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nuclear envelopePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
plasma membraneTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytoplasmTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
mitochondrial matrixTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
early endosomeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endoplasmic reticulumTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytosolTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
mitochondrial cristaTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endosome lumenTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
sorting endosomeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytoplasmic side of endoplasmic reticulum membraneTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein-containing complexTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endoplasmic reticulumTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytoplasmTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
early endosomeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytoplasmPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
cytosolPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
membranePolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
sarcolemmaPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
extracellular exosomePolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
cytosolPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
sarcolemmaPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
photoreceptor outer segmentProstaglandin G/H synthase 1Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 1Homo sapiens (human)
endoplasmic reticulum membraneProstaglandin G/H synthase 1Homo sapiens (human)
Golgi apparatusProstaglandin G/H synthase 1Homo sapiens (human)
intracellular membrane-bounded organelleProstaglandin G/H synthase 1Homo sapiens (human)
extracellular exosomeProstaglandin G/H synthase 1Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 1Homo sapiens (human)
neuron projectionProstaglandin G/H synthase 1Homo sapiens (human)
nuclear inner membraneProstaglandin G/H synthase 2Homo sapiens (human)
nuclear outer membraneProstaglandin G/H synthase 2Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 2Homo sapiens (human)
endoplasmic reticulumProstaglandin G/H synthase 2Homo sapiens (human)
endoplasmic reticulum lumenProstaglandin G/H synthase 2Homo sapiens (human)
endoplasmic reticulum membraneProstaglandin G/H synthase 2Homo sapiens (human)
caveolaProstaglandin G/H synthase 2Homo sapiens (human)
neuron projectionProstaglandin G/H synthase 2Homo sapiens (human)
protein-containing complexProstaglandin G/H synthase 2Homo sapiens (human)
neuron projectionProstaglandin G/H synthase 2Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 2Homo sapiens (human)
platelet alpha granule membraneAlpha-synucleinHomo sapiens (human)
extracellular regionAlpha-synucleinHomo sapiens (human)
extracellular spaceAlpha-synucleinHomo sapiens (human)
nucleusAlpha-synucleinHomo sapiens (human)
cytoplasmAlpha-synucleinHomo sapiens (human)
mitochondrionAlpha-synucleinHomo sapiens (human)
lysosomeAlpha-synucleinHomo sapiens (human)
cytosolAlpha-synucleinHomo sapiens (human)
plasma membraneAlpha-synucleinHomo sapiens (human)
cell cortexAlpha-synucleinHomo sapiens (human)
actin cytoskeletonAlpha-synucleinHomo sapiens (human)
membraneAlpha-synucleinHomo sapiens (human)
inclusion bodyAlpha-synucleinHomo sapiens (human)
axonAlpha-synucleinHomo sapiens (human)
growth coneAlpha-synucleinHomo sapiens (human)
synaptic vesicle membraneAlpha-synucleinHomo sapiens (human)
perinuclear region of cytoplasmAlpha-synucleinHomo sapiens (human)
postsynapseAlpha-synucleinHomo sapiens (human)
supramolecular fiberAlpha-synucleinHomo sapiens (human)
protein-containing complexAlpha-synucleinHomo sapiens (human)
cytoplasmAlpha-synucleinHomo sapiens (human)
axon terminusAlpha-synucleinHomo sapiens (human)
neuronal cell bodyAlpha-synucleinHomo sapiens (human)
lysosomeBeta-secretase 1Homo sapiens (human)
endosomeBeta-secretase 1Homo sapiens (human)
early endosomeBeta-secretase 1Homo sapiens (human)
late endosomeBeta-secretase 1Homo sapiens (human)
multivesicular bodyBeta-secretase 1Homo sapiens (human)
endoplasmic reticulum lumenBeta-secretase 1Homo sapiens (human)
Golgi apparatusBeta-secretase 1Homo sapiens (human)
trans-Golgi networkBeta-secretase 1Homo sapiens (human)
plasma membraneBeta-secretase 1Homo sapiens (human)
synaptic vesicleBeta-secretase 1Homo sapiens (human)
cell surfaceBeta-secretase 1Homo sapiens (human)
endosome membraneBeta-secretase 1Homo sapiens (human)
membraneBeta-secretase 1Homo sapiens (human)
axonBeta-secretase 1Homo sapiens (human)
dendriteBeta-secretase 1Homo sapiens (human)
neuronal cell bodyBeta-secretase 1Homo sapiens (human)
membrane raftBeta-secretase 1Homo sapiens (human)
recycling endosomeBeta-secretase 1Homo sapiens (human)
Golgi-associated vesicle lumenBeta-secretase 1Homo sapiens (human)
hippocampal mossy fiber to CA3 synapseBeta-secretase 1Homo sapiens (human)
endosomeBeta-secretase 1Homo sapiens (human)
plasma membraneBeta-secretase 1Homo sapiens (human)
trans-Golgi networkBeta-secretase 1Homo sapiens (human)
plasma membraneGuanine nucleotide-binding protein GHomo sapiens (human)
cytosolLow molecular weight protein-tyrosine phosphatase AMycobacterium tuberculosis H37Rv
podosomeTyrosine-protein phosphatase non-receptor type 12Homo sapiens (human)
nucleoplasmTyrosine-protein phosphatase non-receptor type 12Homo sapiens (human)
cytosolTyrosine-protein phosphatase non-receptor type 12Homo sapiens (human)
focal adhesionTyrosine-protein phosphatase non-receptor type 12Homo sapiens (human)
cell projectionTyrosine-protein phosphatase non-receptor type 12Homo sapiens (human)
nucleusTyrosine-protein phosphatase non-receptor type 12Homo sapiens (human)
cytoplasmTyrosine-protein phosphatase non-receptor type 12Homo sapiens (human)
centrosomecAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
cytosolcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
plasma membranecAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
apical plasma membranecAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
voltage-gated calcium channel complexcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
calcium channel complexcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
cytosolcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
nucleuscAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
perinuclear region of cytoplasmcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
intracellular non-membrane-bounded organelleTAR DNA-binding protein 43Homo sapiens (human)
nucleusTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
perichromatin fibrilsTAR DNA-binding protein 43Homo sapiens (human)
mitochondrionTAR DNA-binding protein 43Homo sapiens (human)
cytoplasmic stress granuleTAR DNA-binding protein 43Homo sapiens (human)
nuclear speckTAR DNA-binding protein 43Homo sapiens (human)
interchromatin granuleTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
chromatinTAR DNA-binding protein 43Homo sapiens (human)
nucleusTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
cytoplasmTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
cytosolTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
cytoplasmic side of plasma membraneTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
perinuclear region of cytoplasmTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
cytoplasmTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
nucleusTyrosine-protein phosphatase non-receptor type 22Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (151)

Assay IDTitleYearJournalArticle
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1295944Inhibition of EGFR phosphorylation in human U87MG cells measured up to 25 uM after 24 hrs by Western blot analysis2016Journal of natural products, Feb-26, Volume: 79, Issue:2
Morusin Induces TRAIL Sensitization by Regulating EGFR and DR5 in Human Glioblastoma Cells.
AID1331296Inhibition of LPS-induced NO production in mouse RAW264.7 cells measured after 24 hrs by Griess assay2017Bioorganic & medicinal chemistry letters, 01-15, Volume: 27, Issue:2
Bioactive chemical constituents from the root bark of Morus australis.
AID1295922Cytotoxicity against human U87MG cells assessed as cell death after 24 hrs by MTT assay in presence of TRAIL2016Journal of natural products, Feb-26, Volume: 79, Issue:2
Morusin Induces TRAIL Sensitization by Regulating EGFR and DR5 in Human Glioblastoma Cells.
AID593981Inhibition of human recombinant BACE-1 expressed in HEK293 cells assessed as inhibition of amyloid precursor protein cleavage into amyloid beta after 60 mins using Rh-EVNLDAEFK-Quencher as a substrate by FRET assay2011Bioorganic & medicinal chemistry letters, May-15, Volume: 21, Issue:10
Inhibition and structural reliability of prenylated flavones from the stem bark of Morus lhou on β-secretase (BACE-1).
AID1364803Induction of osteoblast proliferation in mouse MC3T3-E1 cells assessed a growth rate relative to untreated control at 10'-6 mol/L after 48 hrs by MTT assay2017Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11
Rapid, microwave-accelerated synthesis and anti-osteoporosis activities evaluation of Morusin scaffolds and Morusignin L scaffolds.
AID1402906Selectivity index, ratio of IC50 for Mycobacterium tuberculosis PtpA to IC50 for Mycobacterium tuberculosis PtpB2018European journal of medicinal chemistry, Jan-20, Volume: 144Naturally occurring Diels-Alder-type adducts from Morus nigra as potent inhibitors of Mycobacterium tuberculosis protein tyrosine phosphatase B.
AID1295966Reduction of XIAP expression in human U373MG cells at 25 uM by Western blot analysis2016Journal of natural products, Feb-26, Volume: 79, Issue:2
Morusin Induces TRAIL Sensitization by Regulating EGFR and DR5 in Human Glioblastoma Cells.
AID403341Inhibition of COX12005Journal of natural products, Jul, Volume: 68, Issue:7
Expanding the ChemGPS chemical space with natural products.
AID1652221Binding affinity to cytosolic region of SERCA1 ATP binding site in NewZealand rabbit SR vesicles assessed as conformational changes by measuring decrease in fluorescence intensity at IC50 incubated for 1 hr by FITC probe labeling based analysis2020ACS medicinal chemistry letters, May-14, Volume: 11, Issue:5
Phenolic Compounds from
AID1295915Induction of DR5 expression in human U373MG cells at 25 uM after 24 hrs by FITC-conjugated flow cytometric analysis2016Journal of natural products, Feb-26, Volume: 79, Issue:2
Morusin Induces TRAIL Sensitization by Regulating EGFR and DR5 in Human Glioblastoma Cells.
AID1295932Reduction of survivin mRNA expression in human U87MG cells after 24 hrs by RT-qPCR analysis2016Journal of natural products, Feb-26, Volume: 79, Issue:2
Morusin Induces TRAIL Sensitization by Regulating EGFR and DR5 in Human Glioblastoma Cells.
AID1295931Reduction of XIAP mRNA expression in human U87MG cells at 25 uM by RT-qPCR analysis2016Journal of natural products, Feb-26, Volume: 79, Issue:2
Morusin Induces TRAIL Sensitization by Regulating EGFR and DR5 in Human Glioblastoma Cells.
AID1627198Cytotoxicity against human MCF7 cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Cytotoxic prenylated flavones from the stem and root bark of Daphne giraldii.
AID1295934Reduction of PDGFR expression in human U373MG cells at 25 uM after 24 hrs by Western blot analysis2016Journal of natural products, Feb-26, Volume: 79, Issue:2
Morusin Induces TRAIL Sensitization by Regulating EGFR and DR5 in Human Glioblastoma Cells.
AID1295959Effect on DR4 expression in human U87MG cells upto 25 uM after 24 hrs by Western blot analysis2016Journal of natural products, Feb-26, Volume: 79, Issue:2
Morusin Induces TRAIL Sensitization by Regulating EGFR and DR5 in Human Glioblastoma Cells.
AID1295929Effect on cIAP1 expression in human U373MG cells at 12 to 25 uM after 24 hrs by Western blot analysis2016Journal of natural products, Feb-26, Volume: 79, Issue:2
Morusin Induces TRAIL Sensitization by Regulating EGFR and DR5 in Human Glioblastoma Cells.
AID1295947Inhibition of EGFR phosphorylation in human U373MG cells measured up to 25 uM after 24 hrs by Western blot analysis2016Journal of natural products, Feb-26, Volume: 79, Issue:2
Morusin Induces TRAIL Sensitization by Regulating EGFR and DR5 in Human Glioblastoma Cells.
AID1402914Selectivity index, ratio of IC50 for PTP-PEST (unknown origin) to IC50 for Mycobacterium tuberculosis PtpB2018European journal of medicinal chemistry, Jan-20, Volume: 144Naturally occurring Diels-Alder-type adducts from Morus nigra as potent inhibitors of Mycobacterium tuberculosis protein tyrosine phosphatase B.
AID1627195Cytotoxicity against human U251 cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Cytotoxic prenylated flavones from the stem and root bark of Daphne giraldii.
AID1295953Effect on DcR2 expression in human U87MG cells upto 25 uM after 24 hrs by Western blot analysis2016Journal of natural products, Feb-26, Volume: 79, Issue:2
Morusin Induces TRAIL Sensitization by Regulating EGFR and DR5 in Human Glioblastoma Cells.
AID1295940Reduction of EGFR expression in human U251MG cells at 25 uM after 24 hrs by Western blot analysis2016Journal of natural products, Feb-26, Volume: 79, Issue:2
Morusin Induces TRAIL Sensitization by Regulating EGFR and DR5 in Human Glioblastoma Cells.
AID1627197Cytotoxicity against human HepG2 cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Cytotoxic prenylated flavones from the stem and root bark of Daphne giraldii.
AID333971Antiplatelet activity against rabbit platelet assessed as inhibition of collagen-induced platelet aggregation at 100 uM preincubated 3 mins before collagen challenge by turbidimetric method relative to control1997Journal of natural products, Oct, Volume: 60, Issue:10
Bioactive constituents of Morus australis and Broussonetia papyrifera.
AID1295907Induction of apoptosis in human T98G cells assessed as increase in cleaved PARP levels at 2.5 uM after 24 hrs by Western blot analysis in presence of TRAIL2016Journal of natural products, Feb-26, Volume: 79, Issue:2
Morusin Induces TRAIL Sensitization by Regulating EGFR and DR5 in Human Glioblastoma Cells.
AID1295952Effect on DcR2 expression in human U251MG cells upto 25 uM after 24 hrs by Western blot analysis2016Journal of natural products, Feb-26, Volume: 79, Issue:2
Morusin Induces TRAIL Sensitization by Regulating EGFR and DR5 in Human Glioblastoma Cells.
AID1295911Induction of DR5 expression in human U373MG cells after 24 hrs by Western blot analysis2016Journal of natural products, Feb-26, Volume: 79, Issue:2
Morusin Induces TRAIL Sensitization by Regulating EGFR and DR5 in Human Glioblastoma Cells.
AID1295948Inhibition of STAT3 phosphorylation in human U373MG cells measured up to 25 uM after 24 hrs by Western blot analysis2016Journal of natural products, Feb-26, Volume: 79, Issue:2
Morusin Induces TRAIL Sensitization by Regulating EGFR and DR5 in Human Glioblastoma Cells.
AID1295917Cytotoxicity against human T98G cells assessed as reduction in cell viability after 24 hrs by MTT assay2016Journal of natural products, Feb-26, Volume: 79, Issue:2
Morusin Induces TRAIL Sensitization by Regulating EGFR and DR5 in Human Glioblastoma Cells.
AID1295937Reduction of PDGFR expression in human U87MG cells at 25 uM after 24 hrs by Western blot analysis2016Journal of natural products, Feb-26, Volume: 79, Issue:2
Morusin Induces TRAIL Sensitization by Regulating EGFR and DR5 in Human Glioblastoma Cells.
AID1331277Cytotoxicity against mouse RAW264.7 cells assessed as cell viability at 12.5 ug/ml measured after 24 hrs in presence of LPS by MTT assay (Rvb = 96.3 +/- 1%)2017Bioorganic & medicinal chemistry letters, 01-15, Volume: 27, Issue:2
Bioactive chemical constituents from the root bark of Morus australis.
AID1331292Inhibition of LPS-induced NO production in mouse RAW264.7 cells at 3.125 ug/ml measured after 24 hrs by Griess assay relative to LPS-treated control2017Bioorganic & medicinal chemistry letters, 01-15, Volume: 27, Issue:2
Bioactive chemical constituents from the root bark of Morus australis.
AID1295895Cytotoxicity against human U251MG cells assessed as reduction in cell viability after 24 hrs by MTT assay2016Journal of natural products, Feb-26, Volume: 79, Issue:2
Morusin Induces TRAIL Sensitization by Regulating EGFR and DR5 in Human Glioblastoma Cells.
AID1295946Inhibition of ERK phosphorylation in human U87MG cells measured up to 25 uM after 24 hrs by Western blot analysis2016Journal of natural products, Feb-26, Volume: 79, Issue:2
Morusin Induces TRAIL Sensitization by Regulating EGFR and DR5 in Human Glioblastoma Cells.
AID1295894Cytotoxicity against human U373MG cells assessed as reduction in cell viability after 24 hrs by MTT assay2016Journal of natural products, Feb-26, Volume: 79, Issue:2
Morusin Induces TRAIL Sensitization by Regulating EGFR and DR5 in Human Glioblastoma Cells.
AID1331287Cytotoxicity against mouse RAW264.7 cells assessed as cell viability at 3.125 ug/ml measured after 24 hrs in presence of LPS by MTT assay (Rvb = 96.3 +/- 1%)2017Bioorganic & medicinal chemistry letters, 01-15, Volume: 27, Issue:2
Bioactive chemical constituents from the root bark of Morus australis.
AID1887298Antibacterial activity against Staphylococcus epidermidis ATCC 51625 assessed as inhibition of bacterial growth incubated for 24 hrs by optical density based analysis2022Journal of natural products, 09-23, Volume: 85, Issue:9
Total Syntheses and Antibacterial Evaluations of Neocyclomorusin and Related Flavones.
AID1331276Cytotoxicity against mouse RAW264.7 cells assessed as cell viability at 25 ug/ml measured after 24 hrs in presence of LPS by MTT assay (Rvb = 96.3 +/- 1%)2017Bioorganic & medicinal chemistry letters, 01-15, Volume: 27, Issue:2
Bioactive chemical constituents from the root bark of Morus australis.
AID1295961Induction of DR5 expression in human U373MG cells at 25 uM by Western blot analysis2016Journal of natural products, Feb-26, Volume: 79, Issue:2
Morusin Induces TRAIL Sensitization by Regulating EGFR and DR5 in Human Glioblastoma Cells.
AID1295962Effect on DR4 expression in human U251MG cells upto 25 uM after 24 hrs by Western blot analysis2016Journal of natural products, Feb-26, Volume: 79, Issue:2
Morusin Induces TRAIL Sensitization by Regulating EGFR and DR5 in Human Glioblastoma Cells.
AID593982Noncompetitive inhibition of human recombinant BACE-1 by Dixon plot analysis2011Bioorganic & medicinal chemistry letters, May-15, Volume: 21, Issue:10
Inhibition and structural reliability of prenylated flavones from the stem bark of Morus lhou on β-secretase (BACE-1).
AID1295958Effect on DR4 expression in human LN18 cells upto 25 uM after 24 hrs by Western blot analysis2016Journal of natural products, Feb-26, Volume: 79, Issue:2
Morusin Induces TRAIL Sensitization by Regulating EGFR and DR5 in Human Glioblastoma Cells.
AID1295918Induction of DR4 expression in human U373MG cells at 25 uM after 24 hrs by FITC-conjugated flow cytometric analysis2016Journal of natural products, Feb-26, Volume: 79, Issue:2
Morusin Induces TRAIL Sensitization by Regulating EGFR and DR5 in Human Glioblastoma Cells.
AID1652228Inhibition of SERCA1 in rat INS-1E cells assessed as insulin release preincubated for 24 hrs followed by incubation in glucose-free buffer and measured after 30 mins by RIA2020ACS medicinal chemistry letters, May-14, Volume: 11, Issue:5
Phenolic Compounds from
AID1295905Induction of apoptosis in human T98G cells assessed as increase in cleaved caspase 9 levels at 2.5 uM after 24 hrs by Western blot analysis in presence of TRAIL2016Journal of natural products, Feb-26, Volume: 79, Issue:2
Morusin Induces TRAIL Sensitization by Regulating EGFR and DR5 in Human Glioblastoma Cells.
AID1887296Antibacterial activity against Escherichia coli ATCC 25922 assessed as inhibition of bacterial growth incubated for 24 hrs by optical density based analysis2022Journal of natural products, 09-23, Volume: 85, Issue:9
Total Syntheses and Antibacterial Evaluations of Neocyclomorusin and Related Flavones.
AID1295964Induction of DR5 expression in human U251MG cells at 25 uM after 24 hrs by FITC-conjugated flow cytometric analysis2016Journal of natural products, Feb-26, Volume: 79, Issue:2
Morusin Induces TRAIL Sensitization by Regulating EGFR and DR5 in Human Glioblastoma Cells.
AID1402912Selectivity index, ratio of IC50 for LYP (unknown origin) to IC50 for Mycobacterium tuberculosis PtpB2018European journal of medicinal chemistry, Jan-20, Volume: 144Naturally occurring Diels-Alder-type adducts from Morus nigra as potent inhibitors of Mycobacterium tuberculosis protein tyrosine phosphatase B.
AID1295912Induction of DR5 expression in human U251MG cells after 24 hrs by Western blot analysis2016Journal of natural products, Feb-26, Volume: 79, Issue:2
Morusin Induces TRAIL Sensitization by Regulating EGFR and DR5 in Human Glioblastoma Cells.
AID403340Inhibition of COX22005Journal of natural products, Jul, Volume: 68, Issue:7
Expanding the ChemGPS chemical space with natural products.
AID1295904Induction of apoptosis in human U87MG cells assessed as increase in cleaved caspase 9 levels at 2.5 uM after 24 hrs by Western blot analysis in presence of TRAIL2016Journal of natural products, Feb-26, Volume: 79, Issue:2
Morusin Induces TRAIL Sensitization by Regulating EGFR and DR5 in Human Glioblastoma Cells.
AID1295967Reduction of survivin expression in human U87MG cells at 25 uM by Western blot analysis2016Journal of natural products, Feb-26, Volume: 79, Issue:2
Morusin Induces TRAIL Sensitization by Regulating EGFR and DR5 in Human Glioblastoma Cells.
AID1364805Induction of osteoblast proliferation in mouse MC3T3-E1 cells assessed a growth rate relative to untreated control at 10'-8 mol/L after 48 hrs by MTT assay2017Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11
Rapid, microwave-accelerated synthesis and anti-osteoporosis activities evaluation of Morusin scaffolds and Morusignin L scaffolds.
AID1295906Induction of apoptosis in human U87MG cells assessed as increase in cleaved PARP levels at 2.5 uM after 24 hrs by Western blot analysis in presence of TRAIL2016Journal of natural products, Feb-26, Volume: 79, Issue:2
Morusin Induces TRAIL Sensitization by Regulating EGFR and DR5 in Human Glioblastoma Cells.
AID1887297Antibacterial activity against Staphylococcus aureus ATCC 25923 assessed as inhibition of bacterial growth incubated for 24 hrs by optical density based analysis2022Journal of natural products, 09-23, Volume: 85, Issue:9
Total Syntheses and Antibacterial Evaluations of Neocyclomorusin and Related Flavones.
AID1295896Cytotoxicity against human U87MG cells assessed as reduction in cell viability measured up to 20 uM after 24 hrs by MTT assay in presence of TRAIL2016Journal of natural products, Feb-26, Volume: 79, Issue:2
Morusin Induces TRAIL Sensitization by Regulating EGFR and DR5 in Human Glioblastoma Cells.
AID1295927Reduction of survivin expression in human U373MG cells after 24 hrs by Western blot analysis2016Journal of natural products, Feb-26, Volume: 79, Issue:2
Morusin Induces TRAIL Sensitization by Regulating EGFR and DR5 in Human Glioblastoma Cells.
AID1402910Selectivity index, ratio of IC50 for human PTP1B to IC50 for Mycobacterium tuberculosis PtpB2018European journal of medicinal chemistry, Jan-20, Volume: 144Naturally occurring Diels-Alder-type adducts from Morus nigra as potent inhibitors of Mycobacterium tuberculosis protein tyrosine phosphatase B.
AID595376Inhibition of 5-LOX2011Journal of natural products, Apr-25, Volume: 74, Issue:4
Natural compound cudraflavone B shows promising anti-inflammatory properties in vitro.
AID1295924Reduction of XIAP expression in human U87MG cells after 24 hrs by Western blot analysis2016Journal of natural products, Feb-26, Volume: 79, Issue:2
Morusin Induces TRAIL Sensitization by Regulating EGFR and DR5 in Human Glioblastoma Cells.
AID1652220Inhibition of SERCA1 in rat INS-1E cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay2020ACS medicinal chemistry letters, May-14, Volume: 11, Issue:5
Phenolic Compounds from
AID1295923Cytotoxicity against human U87MG cells transfected DR5 siRNA assessed as cell death after 24 hrs by MTT assay in presence of TRAIL2016Journal of natural products, Feb-26, Volume: 79, Issue:2
Morusin Induces TRAIL Sensitization by Regulating EGFR and DR5 in Human Glioblastoma Cells.
AID1887299Antibacterial activity against Bacillus subtilis ATCC 11774 assessed as inhibition of bacterial growth incubated for 24 hrs by optical density based analysis2022Journal of natural products, 09-23, Volume: 85, Issue:9
Total Syntheses and Antibacterial Evaluations of Neocyclomorusin and Related Flavones.
AID1295950Effect on DcR2 expression in human LN18 cells upto 25 uM after 24 hrs by Western blot analysis2016Journal of natural products, Feb-26, Volume: 79, Issue:2
Morusin Induces TRAIL Sensitization by Regulating EGFR and DR5 in Human Glioblastoma Cells.
AID1295902Induction of apoptosis in human U87MG cells assessed as increase in cleaved caspase 8 levels at 2.5 uM after 24 hrs by Western blot analysis in presence of TRAIL2016Journal of natural products, Feb-26, Volume: 79, Issue:2
Morusin Induces TRAIL Sensitization by Regulating EGFR and DR5 in Human Glioblastoma Cells.
AID1773061Inhibition of recombinant PTP1B catalytic domain (unknown origin) assessed as reduction in pNP formation using pNPP as substrate at 20 ug/ml by absorbance based analysis relative to control
AID1295939Reduction of EGFR expression in human U373MG cells at 25 uM after 24 hrs by Western blot analysis2016Journal of natural products, Feb-26, Volume: 79, Issue:2
Morusin Induces TRAIL Sensitization by Regulating EGFR and DR5 in Human Glioblastoma Cells.
AID1295960Induction of DR5 expression in human U87MG cells at 25 uM by Western blot analysis2016Journal of natural products, Feb-26, Volume: 79, Issue:2
Morusin Induces TRAIL Sensitization by Regulating EGFR and DR5 in Human Glioblastoma Cells.
AID1295900Induction of apoptosis in human U87MG cells assessed as increase in cleaved caspase 3 levels at 2.5 uM after 24 hrs by Western blot analysis in presence of TRAIL2016Journal of natural products, Feb-26, Volume: 79, Issue:2
Morusin Induces TRAIL Sensitization by Regulating EGFR and DR5 in Human Glioblastoma Cells.
AID1331278Antiplatelet aggregatory activity against New Zealand white rabbit platelets at 100 uM preincubated for 2 to 3 mins followed by ADP-addition measured after 4 mins by turbidometric method relative to vehicle control2017Bioorganic & medicinal chemistry letters, 01-15, Volume: 27, Issue:2
Bioactive chemical constituents from the root bark of Morus australis.
AID1627199Cytotoxicity against human Bcap37 cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Cytotoxic prenylated flavones from the stem and root bark of Daphne giraldii.
AID595370Inhibition of human recombinant COX-2 assessed as PGE2 production from arachidonic acid after 20 mins enzyme immunoassay2011Journal of natural products, Apr-25, Volume: 74, Issue:4
Natural compound cudraflavone B shows promising anti-inflammatory properties in vitro.
AID1295899Cytotoxicity against human U251MG cells assessed as reduction in cell viability measured up to 20 uM after 24 hrs by MTT assay in presence of TRAIL2016Journal of natural products, Feb-26, Volume: 79, Issue:2
Morusin Induces TRAIL Sensitization by Regulating EGFR and DR5 in Human Glioblastoma Cells.
AID1295908Induction of apoptosis in human U87MG cells assessed as apoptic cells at 20 uM after 24 hrs by V-FITC/propidium iodide staining based flow cytometric analysis in presence of TRAIL2016Journal of natural products, Feb-26, Volume: 79, Issue:2
Morusin Induces TRAIL Sensitization by Regulating EGFR and DR5 in Human Glioblastoma Cells.
AID1351564Inhibition of human PDE4D2 catalytic domain (86 to 413 residues) expressed in Escherichia coli strain BL21 using [3H]cAMP as substrate after 15 mins by liquid scintillation counter analysis2018European journal of medicinal chemistry, Jan-20, Volume: 144Prenylated flavonoids as potent phosphodiesterase-4 inhibitors from Morus alba: Isolation, modification, and structure-activity relationship study.
AID1295965Reduction of XIAP expression in human U87MG cells at 25 uM by Western blot analysis2016Journal of natural products, Feb-26, Volume: 79, Issue:2
Morusin Induces TRAIL Sensitization by Regulating EGFR and DR5 in Human Glioblastoma Cells.
AID1295925Reduction of XIAP expression in human U373MG cells after 24 hrs by Western blot analysis2016Journal of natural products, Feb-26, Volume: 79, Issue:2
Morusin Induces TRAIL Sensitization by Regulating EGFR and DR5 in Human Glioblastoma Cells.
AID1295945Inhibition of STAT3 phosphorylation in human U87MG cells measured up to 25 uM after 24 hrs by Western blot analysis2016Journal of natural products, Feb-26, Volume: 79, Issue:2
Morusin Induces TRAIL Sensitization by Regulating EGFR and DR5 in Human Glioblastoma Cells.
AID1402911Inhibition of LYP (unknown origin) using p-nitrophenyl phosphate as substrate preincubated for 10 mins followed by substrate addition measured every minute for 10 mins by UV-VIS spectrophotometric analysis2018European journal of medicinal chemistry, Jan-20, Volume: 144Naturally occurring Diels-Alder-type adducts from Morus nigra as potent inhibitors of Mycobacterium tuberculosis protein tyrosine phosphatase B.
AID1295903Induction of apoptosis in human T98G cells assessed as increase in cleaved caspase 8 levels at 2.5 uM after 24 hrs by Western blot analysis in presence of TRAIL2016Journal of natural products, Feb-26, Volume: 79, Issue:2
Morusin Induces TRAIL Sensitization by Regulating EGFR and DR5 in Human Glioblastoma Cells.
AID1331295Inhibition of LPS-induced NO production in mouse RAW264.7 cells at 12.5 ug/ml measured after 24 hrs by Griess assay relative to LPS-treated control2017Bioorganic & medicinal chemistry letters, 01-15, Volume: 27, Issue:2
Bioactive chemical constituents from the root bark of Morus australis.
AID1295933Reduction of survivin mRNA expression in human U87MG cells at 25 uM by RT-qPCR analysis2016Journal of natural products, Feb-26, Volume: 79, Issue:2
Morusin Induces TRAIL Sensitization by Regulating EGFR and DR5 in Human Glioblastoma Cells.
AID1652227Inhibition of SERCA1 in rat INS-1E cells assessed as induction of apoptosis by measuring increase in late apoptotic cells at IC50 for cell viability incubated for 24 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry2020ACS medicinal chemistry letters, May-14, Volume: 11, Issue:5
Phenolic Compounds from
AID1295955Effect on DcR1 expression in human U251MG cells upto 25 uM after 24 hrs by Western blot analysis2016Journal of natural products, Feb-26, Volume: 79, Issue:2
Morusin Induces TRAIL Sensitization by Regulating EGFR and DR5 in Human Glioblastoma Cells.
AID1190077Induction of apoptosis in TRAIL-resistant human AGS cells assessed as decrease in cell viability at 40 uM after 24 hrs in presence of TRAIL (Rvb = 9%)2015Journal of natural products, Jan-23, Volume: 78, Issue:1
Prenylated flavonoids and resveratrol derivatives isolated from Artocarpus communis with the ability to overcome TRAIL resistance.
AID1295970Effect on cIAP1 expression in human U373MG cells at 25 uM after 3 to 18 hrs by Western blot analysis2016Journal of natural products, Feb-26, Volume: 79, Issue:2
Morusin Induces TRAIL Sensitization by Regulating EGFR and DR5 in Human Glioblastoma Cells.
AID1295910Induction of DR5 expression in human U87MG cells after 24 hrs by Western blot analysis2016Journal of natural products, Feb-26, Volume: 79, Issue:2
Morusin Induces TRAIL Sensitization by Regulating EGFR and DR5 in Human Glioblastoma Cells.
AID1295963Effect on DR4 expression in human U373MG cells upto 25 uM after 24 hrs by Western blot analysis2016Journal of natural products, Feb-26, Volume: 79, Issue:2
Morusin Induces TRAIL Sensitization by Regulating EGFR and DR5 in Human Glioblastoma Cells.
AID1652222Binding affinity to transmembrane region of SERCA1A ATP binding site in NewZealand rabbit SR vesicles assessed as conformational changes by measuring intrinsic Trp fluorescence at IC50 incubated for 30 mins by spectrofluorometric analysis2020ACS medicinal chemistry letters, May-14, Volume: 11, Issue:5
Phenolic Compounds from
AID1295949Inhibition of ERK phosphorylation in human U373MG cells measured up to 25 uM after 24 hrs by Western blot analysis2016Journal of natural products, Feb-26, Volume: 79, Issue:2
Morusin Induces TRAIL Sensitization by Regulating EGFR and DR5 in Human Glioblastoma Cells.
AID1295928Effect on cIAP1 expression in human U87MG cells at 12 to 25 uM after 24 hrs by Western blot analysis2016Journal of natural products, Feb-26, Volume: 79, Issue:2
Morusin Induces TRAIL Sensitization by Regulating EGFR and DR5 in Human Glioblastoma Cells.
AID1295951Effect on DcR2 expression in human U373MG cells upto 25 uM after 24 hrs by Western blot analysis2016Journal of natural products, Feb-26, Volume: 79, Issue:2
Morusin Induces TRAIL Sensitization by Regulating EGFR and DR5 in Human Glioblastoma Cells.
AID1295921Induction of DR5 mRNA expression in human U87MG cells at 25 uM after 24 hrs by RT-qPCR analysis2016Journal of natural products, Feb-26, Volume: 79, Issue:2
Morusin Induces TRAIL Sensitization by Regulating EGFR and DR5 in Human Glioblastoma Cells.
AID595393Inhibition of ram seminal vesicle COX-1 assessed as PGE2 production from arachidonic acid after 20 mins enzyme immunoassay2011Journal of natural products, Apr-25, Volume: 74, Issue:4
Natural compound cudraflavone B shows promising anti-inflammatory properties in vitro.
AID1364802Induction of osteoblast proliferation in mouse MC3T3-E1 cells assessed as growth rate relative to untreated control at 10'-5 mol/L after 48 hrs by MTT assay2017Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11
Rapid, microwave-accelerated synthesis and anti-osteoporosis activities evaluation of Morusin scaffolds and Morusignin L scaffolds.
AID1295942Reduction of EGFR expression in human U87MG cells at 25 uM after 24 hrs by Western blot analysis2016Journal of natural products, Feb-26, Volume: 79, Issue:2
Morusin Induces TRAIL Sensitization by Regulating EGFR and DR5 in Human Glioblastoma Cells.
AID1295919Induction of DR4 expression in human U87MG cells at 25 uM after 24 hrs by FITC-conjugated flow cytometric analysis2016Journal of natural products, Feb-26, Volume: 79, Issue:2
Morusin Induces TRAIL Sensitization by Regulating EGFR and DR5 in Human Glioblastoma Cells.
AID333973Antiplatelet activity against rabbit platelet assessed as inhibition of arachidonic acid-induced platelet aggregation at 50 uM preincubated 3 mins before arachidonic acid challenge by turbidimetric method relative to control1997Journal of natural products, Oct, Volume: 60, Issue:10
Bioactive constituents of Morus australis and Broussonetia papyrifera.
AID1295956Effect on DcR1 expression in human U87MG cells upto 25 uM after 24 hrs by Western blot analysis2016Journal of natural products, Feb-26, Volume: 79, Issue:2
Morusin Induces TRAIL Sensitization by Regulating EGFR and DR5 in Human Glioblastoma Cells.
AID595377Inhibition of 12-LOX2011Journal of natural products, Apr-25, Volume: 74, Issue:4
Natural compound cudraflavone B shows promising anti-inflammatory properties in vitro.
AID1295930Reduction of XIAP mRNA expression in human U87MG cells after 24 hrs by RT-qPCR analysis2016Journal of natural products, Feb-26, Volume: 79, Issue:2
Morusin Induces TRAIL Sensitization by Regulating EGFR and DR5 in Human Glioblastoma Cells.
AID1295941Reduction of EGFR expression in human T98G cells at 25 uM after 24 hrs by Western blot analysis2016Journal of natural products, Feb-26, Volume: 79, Issue:2
Morusin Induces TRAIL Sensitization by Regulating EGFR and DR5 in Human Glioblastoma Cells.
AID1295920Induction of DR4 expression in human U251MG cells at 25 uM after 24 hrs by FITC-conjugated flow cytometric analysis2016Journal of natural products, Feb-26, Volume: 79, Issue:2
Morusin Induces TRAIL Sensitization by Regulating EGFR and DR5 in Human Glioblastoma Cells.
AID1364804Induction of osteoblast proliferation in mouse MC3T3-E1 cells assessed a growth rate relative to untreated control at 10'-7 mol/L after 48 hrs by MTT assay2017Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11
Rapid, microwave-accelerated synthesis and anti-osteoporosis activities evaluation of Morusin scaffolds and Morusignin L scaffolds.
AID333972Antiplatelet activity against rabbit platelet assessed as inhibition of platelet-activating factor-induced platelet aggregation at 100 uM preincubated 3 mins before PAF challenge by turbidimetric method relative to control1997Journal of natural products, Oct, Volume: 60, Issue:10
Bioactive constituents of Morus australis and Broussonetia papyrifera.
AID333974Antiplatelet activity against rabbit platelet assessed as inhibition of platelet-activating factor-induced platelet aggregation at 50 uM preincubated 3 mins before PAF challenge by turbidimetric method relative to control1997Journal of natural products, Oct, Volume: 60, Issue:10
Bioactive constituents of Morus australis and Broussonetia papyrifera.
AID1295954Effect on DcR1 expression in human LN18 cells upto 25 uM after 24 hrs by Western blot analysis2016Journal of natural products, Feb-26, Volume: 79, Issue:2
Morusin Induces TRAIL Sensitization by Regulating EGFR and DR5 in Human Glioblastoma Cells.
AID1295971Stability in human U87MG cells assessed as compound remaining at 10 uM after 24 hrs2016Journal of natural products, Feb-26, Volume: 79, Issue:2
Morusin Induces TRAIL Sensitization by Regulating EGFR and DR5 in Human Glioblastoma Cells.
AID1295943Reduction of EGFR expression in human LN18 cells at 25 uM after 24 hrs by Western blot analysis2016Journal of natural products, Feb-26, Volume: 79, Issue:2
Morusin Induces TRAIL Sensitization by Regulating EGFR and DR5 in Human Glioblastoma Cells.
AID333969Antiplatelet activity against rabbit platelet assessed as inhibition of thrombin-induced platelet aggregation at 100 uM preincubated 3 mins before thrombin challenge by turbidimetric method1997Journal of natural products, Oct, Volume: 60, Issue:10
Bioactive constituents of Morus australis and Broussonetia papyrifera.
AID1331288Cytotoxicity against mouse RAW264.7 cells assessed as cell viability at 6.25 ug/ml measured after 24 hrs in presence of LPS by MTT assay (Rvb = 96.3 +/- 1%)2017Bioorganic & medicinal chemistry letters, 01-15, Volume: 27, Issue:2
Bioactive chemical constituents from the root bark of Morus australis.
AID1331282Antiplatelet aggregatory activity against New Zealand white rabbit platelets at 100 uM preincubated for 2 to 3 mins followed by PAF-addition measured after 4 mins by turbidometric method relative to vehicle control2017Bioorganic & medicinal chemistry letters, 01-15, Volume: 27, Issue:2
Bioactive chemical constituents from the root bark of Morus australis.
AID1295916Cytotoxicity against human LN18 cells assessed as reduction in cell viability after 24 hrs by MTT assay2016Journal of natural products, Feb-26, Volume: 79, Issue:2
Morusin Induces TRAIL Sensitization by Regulating EGFR and DR5 in Human Glioblastoma Cells.
AID1295968Reduction of survivin expression in human U373MG cells at 25 uM by Western blot analysis2016Journal of natural products, Feb-26, Volume: 79, Issue:2
Morusin Induces TRAIL Sensitization by Regulating EGFR and DR5 in Human Glioblastoma Cells.
AID1627196Cytotoxicity against human A549 cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Cytotoxic prenylated flavones from the stem and root bark of Daphne giraldii.
AID1331289Cytotoxicity against mouse RAW264.7 cells assessed as cell viability at 50 ug/ml measured after 24 hrs in presence of LPS by MTT assay (Rvb = 96.3 +/- 1%)2017Bioorganic & medicinal chemistry letters, 01-15, Volume: 27, Issue:2
Bioactive chemical constituents from the root bark of Morus australis.
AID1402913Inhibition of PTP-PEST (unknown origin) using p-nitrophenyl phosphate as substrate preincubated for 10 mins followed by substrate addition measured every minute for 10 mins by UV-VIS spectrophotometric analysis2018European journal of medicinal chemistry, Jan-20, Volume: 144Naturally occurring Diels-Alder-type adducts from Morus nigra as potent inhibitors of Mycobacterium tuberculosis protein tyrosine phosphatase B.
AID1295893Cytotoxicity against human U138MG cells assessed as reduction in cell viability after 24 hrs by MTT assay2016Journal of natural products, Feb-26, Volume: 79, Issue:2
Morusin Induces TRAIL Sensitization by Regulating EGFR and DR5 in Human Glioblastoma Cells.
AID1402908Inhibition of Mycobacterium tuberculosis PtpA using p-nitrophenyl phosphate as substrate preincubated for 10 mins followed by substrate addition measured every minute for 10 mins by UV-VIS spectrophotometric analysis2018European journal of medicinal chemistry, Jan-20, Volume: 144Naturally occurring Diels-Alder-type adducts from Morus nigra as potent inhibitors of Mycobacterium tuberculosis protein tyrosine phosphatase B.
AID1295914Induction of DR5 expression in human U87MG cells at 25 uM after 24 hrs by FITC-conjugated flow cytometric analysis2016Journal of natural products, Feb-26, Volume: 79, Issue:2
Morusin Induces TRAIL Sensitization by Regulating EGFR and DR5 in Human Glioblastoma Cells.
AID1652224Inhibition of SERCA1 in glucose-stimulated rat INS-1E cells assessed as decline in insulin release preincubated for 24 hrs followed by glucose addition and measured after 30 mins by RIA2020ACS medicinal chemistry letters, May-14, Volume: 11, Issue:5
Phenolic Compounds from
AID1652226Inhibition of SERCA1 in rat INS-1E cells assessed as induction of apoptosis by measuring increase in early apoptotic cells at IC50 for cell viability incubated for 24 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry2020ACS medicinal chemistry letters, May-14, Volume: 11, Issue:5
Phenolic Compounds from
AID1295926Reduction of survivin expression in human U87MG cells after 24 hrs by Western blot analysis2016Journal of natural products, Feb-26, Volume: 79, Issue:2
Morusin Induces TRAIL Sensitization by Regulating EGFR and DR5 in Human Glioblastoma Cells.
AID1331293Inhibition of LPS-induced NO production in mouse RAW264.7 cells at 6.25 ug/ml measured after 24 hrs by Griess assay relative to LPS-treated control2017Bioorganic & medicinal chemistry letters, 01-15, Volume: 27, Issue:2
Bioactive chemical constituents from the root bark of Morus australis.
AID1402909Inhibition of human PTP1B using p-nitrophenyl phosphate as substrate preincubated for 10 mins followed by substrate addition measured every minute for 10 mins by UV-VIS spectrophotometric analysis2018European journal of medicinal chemistry, Jan-20, Volume: 144Naturally occurring Diels-Alder-type adducts from Morus nigra as potent inhibitors of Mycobacterium tuberculosis protein tyrosine phosphatase B.
AID1652219Inhibition of SERCA1 in NewZealand rabbit skeletal muscle SR vesicles using ATP as substrate incubated for 2 mins followed by Ca2+ addition by NADH coupled enzyme assay2020ACS medicinal chemistry letters, May-14, Volume: 11, Issue:5
Phenolic Compounds from
AID1295909Induction of apoptosis in human T98G cells assessed as apoptic cells at 20 uM after 24 hrs by V-FITC/propidium iodide staining based flow cytometric analysis in presence of TRAIL2016Journal of natural products, Feb-26, Volume: 79, Issue:2
Morusin Induces TRAIL Sensitization by Regulating EGFR and DR5 in Human Glioblastoma Cells.
AID1773062Inhibition of recombinant PTP1B catalytic domain (unknown origin) assessed as reduction in pNP formation using pNPP as substrate by absorbance based analysis
AID1295892Cytotoxicity against human U87MG cells assessed as reduction in cell viability after 24 hrs by MTT assay2016Journal of natural products, Feb-26, Volume: 79, Issue:2
Morusin Induces TRAIL Sensitization by Regulating EGFR and DR5 in Human Glioblastoma Cells.
AID1295969Effect on cIAP1 expression in human U87MG cells at 25uM after 3 to 18 hrs by Western blot analysis2016Journal of natural products, Feb-26, Volume: 79, Issue:2
Morusin Induces TRAIL Sensitization by Regulating EGFR and DR5 in Human Glioblastoma Cells.
AID333970Antiplatelet activity against rabbit platelet assessed as inhibition of arachidonic acid-induced platelet aggregation at 100 uM preincubated 3 mins before arachidonic acid challenge by turbidimetric method relative to control1997Journal of natural products, Oct, Volume: 60, Issue:10
Bioactive constituents of Morus australis and Broussonetia papyrifera.
AID1295957Effect on DcR1 expression in human U373MG cells upto 25 uM after 24 hrs by Western blot analysis2016Journal of natural products, Feb-26, Volume: 79, Issue:2
Morusin Induces TRAIL Sensitization by Regulating EGFR and DR5 in Human Glioblastoma Cells.
AID1652225Inhibition of SERCA1 in rat INS-1E cells assessed as induction of apoptosis by measuring decrease in living cells at IC50 for cell viability incubated for 24 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry2020ACS medicinal chemistry letters, May-14, Volume: 11, Issue:5
Phenolic Compounds from
AID1295935Reduction of PDGFR expression in human U251MG cells at 25 uM after 24 hrs by Western blot analysis2016Journal of natural products, Feb-26, Volume: 79, Issue:2
Morusin Induces TRAIL Sensitization by Regulating EGFR and DR5 in Human Glioblastoma Cells.
AID1295938Reduction of PDGFR expression in human LN18 cells at 25 uM after 24 hrs by Western blot analysis2016Journal of natural products, Feb-26, Volume: 79, Issue:2
Morusin Induces TRAIL Sensitization by Regulating EGFR and DR5 in Human Glioblastoma Cells.
AID1331280Antiplatelet aggregatory activity against New Zealand white rabbit platelets at 100 uM preincubated for 2 to 3 mins followed by arachidonic acid -addition measured after 4 mins by turbidometric method relative to vehicle control2017Bioorganic & medicinal chemistry letters, 01-15, Volume: 27, Issue:2
Bioactive chemical constituents from the root bark of Morus australis.
AID1295898Cytotoxicity against human U373MG cells assessed as reduction in cell viability measured up to 20 uM after 24 hrs by MTT assay in presence of TRAIL2016Journal of natural products, Feb-26, Volume: 79, Issue:2
Morusin Induces TRAIL Sensitization by Regulating EGFR and DR5 in Human Glioblastoma Cells.
AID1295913Induction of DR5 expression in human LN18 cells after 24 hrs by Western blot analysis2016Journal of natural products, Feb-26, Volume: 79, Issue:2
Morusin Induces TRAIL Sensitization by Regulating EGFR and DR5 in Human Glioblastoma Cells.
AID1295897Cytotoxicity against human T98G cells assessed as reduction in cell viability measured up to 20 uM after 24 hrs by MTT assay in presence of TRAIL2016Journal of natural products, Feb-26, Volume: 79, Issue:2
Morusin Induces TRAIL Sensitization by Regulating EGFR and DR5 in Human Glioblastoma Cells.
AID1295936Reduction of PDGFR expression in human T98G cells at 25 uM after 24 hrs by Western blot analysis2016Journal of natural products, Feb-26, Volume: 79, Issue:2
Morusin Induces TRAIL Sensitization by Regulating EGFR and DR5 in Human Glioblastoma Cells.
AID1295901Induction of apoptosis in human T98G cells assessed as increase in cleaved caspase 3 levels at 2.5 uM after 24 hrs by Western blot analysis in presence of TRAIL2016Journal of natural products, Feb-26, Volume: 79, Issue:2
Morusin Induces TRAIL Sensitization by Regulating EGFR and DR5 in Human Glioblastoma Cells.
AID333975Antiplatelet activity against rabbit platelet assessed as inhibition of arachidonic acid-induced platelet aggregation at 20 uM preincubated 3 mins before arachidonic acid challenge by turbidimetric method relative to control1997Journal of natural products, Oct, Volume: 60, Issue:10
Bioactive constituents of Morus australis and Broussonetia papyrifera.
AID1402907Inhibition of Mycobacterium tuberculosis PtpB using p-nitrophenyl phosphate as substrate preincubated for 10 mins followed by substrate addition measured every minute for 10 mins by UV-VIS spectrophotometric analysis2018European journal of medicinal chemistry, Jan-20, Volume: 144Naturally occurring Diels-Alder-type adducts from Morus nigra as potent inhibitors of Mycobacterium tuberculosis protein tyrosine phosphatase B.
AID333976Antiplatelet activity against rabbit platelet assessed as inhibition of platelet-activating factor-induced platelet aggregation at 20 uM preincubated 3 mins before PAF challenge by turbidimetric method relative to control1997Journal of natural products, Oct, Volume: 60, Issue:10
Bioactive constituents of Morus australis and Broussonetia papyrifera.
AID1799721Tyrosinase Assay from Article 10.1080/14756360701810207: \\Inhibitory effects on mushroom tyrosinase by flavones from the stem barks of Morus lhou (S.) Koidz.\\2008Journal of enzyme inhibition and medicinal chemistry, Dec, Volume: 23, Issue:6
Inhibitory effects on mushroom tyrosinase by flavones from the stem barks of Morus lhou (S.) Koidz.
AID1159585Biochemical screen of P. falciparum CDPK12016PloS one, , Volume: 11, Issue:3
Biochemical Screening of Five Protein Kinases from Plasmodium falciparum against 14,000 Cell-Active Compounds.
AID1159586Biochemical screen of P. falciparum PK62016PloS one, , Volume: 11, Issue:3
Biochemical Screening of Five Protein Kinases from Plasmodium falciparum against 14,000 Cell-Active Compounds.
AID1159588Biochemical screen of P. falciparum CDPK42016PloS one, , Volume: 11, Issue:3
Biochemical Screening of Five Protein Kinases from Plasmodium falciparum against 14,000 Cell-Active Compounds.
AID1159587Biochemical screen of P. falciparum PK72016PloS one, , Volume: 11, Issue:3
Biochemical Screening of Five Protein Kinases from Plasmodium falciparum against 14,000 Cell-Active Compounds.
AID1159589Biochemical screen of P. falciparum MAPK22016PloS one, , Volume: 11, Issue:3
Biochemical Screening of Five Protein Kinases from Plasmodium falciparum against 14,000 Cell-Active Compounds.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (74)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (1.35)18.7374
1990's3 (4.05)18.2507
2000's7 (9.46)29.6817
2010's37 (50.00)24.3611
2020's26 (35.14)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 30.96

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index30.96 (24.57)
Research Supply Index4.36 (2.92)
Research Growth Index5.65 (4.65)
Search Engine Demand Index39.34 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (30.96)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (1.32%)5.53%
Reviews3 (3.95%)6.00%
Case Studies0 (0.00%)4.05%
Observational1 (1.32%)0.25%
Other71 (93.42%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]